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RETROSPECTIVE AND REAL-TIME SEMICONDUCTOR
DOSIMETRY: APPLICATIONS TO GEOLOGICAL DATING AND
BRACHYTHERAPY QUALITY ASSURANCE
Anna A. Romanyukha
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ABSTRACT
In this thesis solid state semiconductor dosimetry is applied to the
improvement of luminescence dating techniques (part 1) and quality assurance in
high dose rate (HDR) brachytherapy (BT) cancer treatments (part 2).
The aim of part 1 is the development, testing, and application of a novel
method to measure spatially resolved dose rates in sediment samples using the
Timepix pixelated detector. The Timepix contains an array of 256x256 pixels, each
55x55 μm in size and with its own preamplifier, discriminator and digital counter,
and is able to provide the position and pixel-by-pixel count rate of the incident
radiation. The development of a method to measure sediment samples and derive
spatially resolved dose rates is described, followed by its application to sediment
samples from Liang Bua and Denisova Cave archeological sites.
Part 2 focuses on the application of real time in vivo dosimetry for HDR BT
treatment verification. MOSkin dosimeters were selected due to their small size and
capability of measuring steep dose gradients, such as those characteristic of the HDR
source. Three MOSkins were placed on a rectal probe to verify doses to the rectal
wall in gynecological BT treatments. A feasibility study and the in vivo application of
the proposed method to patient treatments at the Istituto Nazionale dei Tumori
(INT) are described. Furthermore, a system for real time tracking of the HDR source
is proposed by embedding epitaxial diodes on the surface of a multichannel vaginal
cylinder (MVC). The ability of the developed system to verify positions and dwell
times of the HDR source was tested using simple dwell positions and dwell times,
followed by the retrospective delivery of 10 clinical plans previously delivered to
patients undergoing adjuvant vaginal cuff BT after hysterectomy at INT.

KEYWORDS: Solid state dosimetry, spatially resolved radioactivity, Timepix,
sediment dating, in vivo dosimetry, HDR brachytherapy, MOSFET, gynecological
brachytherapy, diodes, multichannel vaginal applicator.
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Chapter 1
Introduction
Radiation has influenced many spheres of our lives. It is applied to chronological
dating of objects and events, as well as for various medical applications that include
the diagnosis and treatment of skeletal, vascular, and soft-tissue diseases. Its farreaching potential can be exemplified by the distant places where nuclear energy is
used: in our homes, on submarines and satellites.
Radioactivity is the product of the transition of an unstable nucleus to a stable, or
more stable state. Radioactive elements are inherent to Earth’s geological
composition, where they are most abundant in the uranium, thorium, and potassium
decay chains. Radioisotopes can also be produced artificially by neutron
bombardment or through the interaction of charged particle accelerator beams with
a target. Natural radioisotopes, such as 238U, 232Th and 40K, are used for sediment
dating; artificially produced radioisotopes, such as 192Ir, 60Co, 103Pd, 125I and 131I are
employed in radiotherapy cancer treatments. Thus, through the correct
chronological placement of sediments, radiation can be the key to understanding the
past, and, by advancing radiotherapy treatments, it can improve the quality of life of
present and future populations.
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Modern humans had evolved into their current anatomical structure by about
200,000 years (ka) ago in Africa. From there on we, Homo sapiens (Latin for “wise”),
have advanced via natural selection while dispersing and adapting to habitats
inherent to the various continents and regions. Ancient civilizations cultivated a
culture and with it an awareness of history. However the wide belief that we were
the only Homo species to have inhabited Earth persisted, until the discovery of the
Neanderthals in the nineteenth century [1]. Further discoveries of species from the
Homo genus have shed some light on a previously unknown world of the Homo
erectus, Homo heidelbergensis, and Homo habilis, among others. These discoveries
have only taken place in the last 120 years, with the most recent skeletons of Homo
naledi found by cavers in South Africa in 2013 [2].
Denisovans and Homo floresiensis are among the most recent additions to the Homo
genus, discovered in 2010 and 2003, respectively. Both species inhabited Earth
alongside H. sapiens for hundreds of thousands of years and eventually became
extinct. Denisovans were discovered in the Denisova Cave in the Altai region of
Russia. The Indonesian “hobbit” species was found in the cave Liang Bua on the
island of Flores. Both are thought to have existed at these sites in the period of 200
to 50 ka ago, lived, and possibly interbred, particularly in the case of the former,
with modern-day humans [3]. Although bone fragments of the Denisovans were
uncovered in Russia, it has been postulated that the species covered a wide
geographical scope, with DNA-based evidence suggesting that these could
potentially be the widest-spreading species after modern humans [4]. Both of these
ancient hominins eventually became extinct, whereas we, the modern-day humans,
continued to evolve into the society we comprise today.
Over thousands of years the “wise men” proved themselves to be fitter for life on
Earth than the rest of the members of the Homo genus. Humans started dispersing
out of the African niche 60 ka years ago, and at about 10 ka ago a shift in human life
patterns occurred, taking us from a hunting-and-gathering society into a more
settled way of life, with agriculture at its center. Our species continued to evolve,
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eventually bringing about industrialization, and with it considerable changes to the
structure of human life. Humans have progressed through a variety of lifestyles that
appear to affect, among others, the patterns of population morbidity [5]. The major
cause of death in human populations has evolved from injury/violence to infectious
disease and chronic disease, respectively, and finally arrived at cancer — one of the
most pervasive diseases currently known to humans. Annually cancer has led to the
death of 8.8 million people [6], and has been dubbed the “Emperor of all Maladies”
by one of the most prominent contemporary oncologist-writers, Siddhartha
Mukherjee. 14.1 million new cancer cases were reported worldwide in 2012, and
this number is expected to increase to 23.6 million by the year 2030 [7].
Approximately half of all cancer patients undergo radiotherapy treatments,
sometimes as the sole treatment, or often combined with other treatment
modalities, including surgery, chemotherapy, and immunotherapy. Brachytherapy is
radiotherapy delivered directly into or in close proximity to the target, allowing
increased doses to the target, while sparing the surrounding healthy tissues. The
complexity of radiotherapy techniques is constantly rising, with sophisticated
methods such as the introduction of additional accessories (i.e., multiple needles in
brachytherapy) and devices (i.e., organ motion trackers) that allow better targeting,
but also more room for errors to occur. The integration of radiation measurements
into clinical routines is able to provide an independent mode of treatment
verification, and thus ensure that the treatment has been delivered as intended by
the hospital staff, making radiation measurements an integral part of optimal
clinical outcomes.
Despite the fact that H. sapiens has overcome challenges insurmountable to our
fellow hominins, effective cancer treatment remains a challenge. Cancer treatment
procedures are still in need of development and improvement to achieve the highest
quality of cancer care possible, and subsequently, increase the quality and longevity
of life for the cancer patient. The advancement of radiation measurement
techniques is imperative in order to gain a better understanding of the past and the
future of our species. It is important that we apply the unique properties of
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radiation in order to learn patterns of the dispersal of our predecessors on Earth,
and why they came to be extinct, all the meanwhile continuing to tackle the
obstacles of contemporary life. The “wise man” is one who lives consciously: aware
of the past, and capable of shaping a future where our species continue to thrive on
Earth.

1.1

Thesis aims

This thesis is unique because it combines two distinct areas of research through the
application of solid-state semiconductor dosimetry: archeology and radiotherapy.
These two interdisciplinary studies, in a sense, relate to both the ancient and the
modern human race. The “ancient” dosimetry study aims to improve luminescencebased dating techniques to gain further insight into the past, while the “modern”
aims to advance cancer treatment procedures for the benefit of future generations
of oncology patients.
This dissertation is divided into two parts: the “ancient” i.e., retrospective
dosimetry, and the “modern” i.e., real-time dosimetry. Chapters 2 and 10 stand
outside the two parts, and serve as the introduction and conclusion to the respective
topics. Chapter 2 outlines the basic concepts in solid-state semiconductor dosimetry
and introduces the differences between its applications to luminescence dating and
medical physics, respectively. Chapter 10 addresses the recommendations and
conclusions of both the retrospective and real-time dosimetry research projects.
The aims of this thesis are the:
1. Development, testing, and application of a novel method to measure spatially
resolved dose rates in sediment samples using the Timepix pixelated
detector.
2. Feasibility and application of rectal wall in vivo dosimetry (IVD) in
gynecological brachytherapy treatment employing MOSkin dosimeters.
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3. Development and verification of an innovative brachytherapy applicator for
gynecological brachytherapy with an embedded real-time high dose rate
source verification system using epitaxial diodes.

1.2

Thesis outline

Part 1 addresses the first aim, and includes chapters 3 through 6. Chapter 3
describes the main concepts in luminescence dating and how sediment age is
derived, followed by a more detailed statement of the retrospective dosimetry study
aims. Chapter 4 addresses the particular issue of inhomogeneity of radiation within
sediment samples, and describes previous research and its existing limitations. The
proposed solution — a novel method utilizing the Timepix detector, and the initial
feasibility studies are described. Chapter 5 outlines the development of the
proposed novel methodology: the measurement and data analysis procedure to
extract spatially resolved dose rates in sediment samples using the Timepix
detector. This chapter includes a description of the Geant4 simulation component,
sample preparation and measurement setup, and the Timepix count rate to
environmental dose rate calibration procedures. The application of the developed
method to sediment samples, including an artificial stratified sample, and sediment
samples from the Liang Bua and Denisova caves, is then addressed in chapter 6.
Part 2 includes chapters 7 through 9. Chapter 7 explains the rationale for real-time
treatment verification and the specific dose calculation method applied in
brachytherapy (i.e., the radiotherapy treatment of interest in this study).
Gynecological high dose rate (HDR) brachytherapy treatments are introduced, and
the requirements of an effective real-time treatment verification system are
outlined. Two possible methods of real time in vivo dose verification are introduced:
dosimetry via placement of miniature detectors in points of interest, and source
tracking to match the planned dwell positions and times to the delivered treatment.
Chapter 8 addresses the second thesis aim, and describes MOSkin dosimeters and
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the proposed IVD system. Section 8.4 describes the proposed simplified method for
MOSkin calibration adjustment for IVD dosimetry in the clinic, and sections 8.5 and
8.6 present the completed IVD patient study and conclusions, respectively. Chapter
9 addresses the third thesis aim, and is dedicated to the proposed real-time
radiation tracking system employing innovative epi diodes. An overview of HDR
brachytherapy source tracking as a method for treatment verification is addressed
in section 9.1; section 9.2 presents a more detailed statement of the study aims. The
radiation resistant epitaxial diodes and the novel multichannel vaginal cylinder
(MVC) applicator system developed to address existing shortcomings in source
tracking methods are described in sections 9.3 and 9.4. The application and
verification studies of the MVC applicator system are discussed in section 9.5.
Section 9.6 focuses on recommendations and conclusions of the MVC system’s
application for real-time brachytherapy treatment verification.
Chapter 10 concludes with a summary of the achievements of both the “ancient” and
“modern” dosimetry projects, followed by recommendations of the potential future
improvements to the proposed methodologies, and the final conclusions.

Chapter 2
Solid-state semiconductor dosimetry: the
basics
Radiation can be measured using a number of techniques and materials that include
gas-filled chambers, film, and scintillation and solid-state semiconductor materials.
The latter is the focus of this thesis. Initial research on solid-state methods focused
on thermoluminescence dosimetry (TLD), with Daniels et al. (1953) [8] applying
solid-state dosimetry to both radiation protection and dating of geological material.

2.1

Solid-state semiconductors and band theory

Solids are classified according to the mobility of electrons in response to an electric
field, which is further characterized by the crystal structure and band gap [9]. Solids
are identified as conductors, semiconductors, or insulators. Crystalline solids have
regular repeated atomic arrangements in a lattice, and are further subdivided into
covalent solids, with adjacent atoms covalently bound by shared valence electrons.
These are very hard and have high melting points, and since they do not have free
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electrons they are poor conductors of electricity. Examples include copper
(conductor), silicon (semiconductor), and diamond (insulator).

Figure 2.1 Band gap structures of crystalline solids.
A band gap exists between the valence and conduction bands, called the forbidden
gap. In insulators, the forbidden gap is ≥5 eV, in semiconductors it is ~1 eV, and in
conductors the bands merge together, allowing mobility of valence electrons
between the gaps (Fig. 2.1). Electrons can be promoted from the valence band to the
conduction band through ionizations, thermal fluctuations, and the absorption of
photons. Semiconductors allow some mobility of valence electrons into the
conduction band at room temperature, giving electrons conductivity. An electric
field causes motion of electron-hole pairs, thus contributing to conductivity and
creating further holes to be filled with electrons. Conductivity is enhanced through
a process called doping: in order to add impurities and increase conductivity,
electrons are injected into the conduction band (n-type semiconductor), or extra
holes are added to the valence band (p-type semiconductor). In turn, removing
electrons from the valence band decreases conductivity and increases resistivity.
An intrinsic semiconductor is one that has a perfect balance between electrons and
holes; in reality, however, some impurities exist in materials. Silicon and germanium
are considered to have optimal natural impurities. Silicon in particular has been
widely used due to its ability to tolerate high electrical currents without succumbing
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to the production of free electrons and holes (i.e., an avalanche breakdown). It has
become available in the realm of radiation detection since the 1960s. Its forbidden
gap is about 1.14 eV, and the W value (the energy required to liberate one electronhole pair created by incident radiation) is 3.6 eV.
Solid-state semiconductor dosimetry dominates over other dosimetry methods for
properties including:
•

high energy resolution due to the capability of producing a high number of
information carriers per radiation event;

•

convenient size, as compared to bulky ionization chambers;

•

possibility to vary the effective thickness of the sensor depending on the
type and energy of the measured event.

2.2

Radiation dosimetry

This field of dosimetry deals with the quantification of radiation absorbed in its
various forms, including photons, electrons, alpha particles, neutrons, protons, and
various cosmic emissions (e.g., muons and pions). This thesis will focus on the
measurement of electrons, since they are the main particle associated with natural
potassium, and photons, used in radiotherapy.
Electrons are charged particles, and thus deposit their energy through direct
interactions with the medium they enter, exciting and ionizing atoms, as well as
emitting energy via bremsstrahlung. They often undergo multiple scatterings, and
can lose their energy quickly in collisions with the electrons of the medium. Energy
loss occurs at a steady pace. Photons, on the other hand, are neutral particles and
deposit their energy through secondary interactions produced in the photon
interactions with the medium. They can keep traveling within the medium before
interaction occurs. The photoelectric effect dominates photon interactions at
energies of <100 keV (dependent on material), where photoelectric absorption of
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the incident photon occurs, completely transferring its energy to an electron. The
electron is then emitted, accompanied by an Auger electron or a secondary photon.
Compton scattering dominates for photons of energy between 100 keV and 10 MeV,
where the photon transfers some of its energy to an electron, and then scatters. Pair
production dominates at energies above 10 MeV, requiring a minimum photon
energy of 1.022 MeV, and results in an electron and positron.
The junction of n-type and p-type semiconductors is especially relevant in radiation
dosimetry. The boundary region between the two is called the depletion region and
is almost entirely free of charge carriers. A potential applied to the region sweeps
out the created charge carriers, with electrons going toward the n- side and holes
toward p- side. Altering the bias voltage can change the physical size of the
depletion region. The number of electron-hole pairs produced is proportional to the
absorbed energy.
Dosimetry is the measure of radiation energy absorbed per unit mass, and is most
commonly measured in the SI unit of Gray, where 1 Gray equals 1 Joule/kilogram.
Absorbed dose D is defined by the International Organization for Standardization
according to:
!!

! = !"

(2.1)

where !! is the mean energy imparted to matter of mass !" [10].
Hereafter, the concept of dose branches out into the respective fields of
luminescence dating and medical physics.
2.2.1 Dose: luminescence dating
Quartz and feldpspar, the two most abundant minerals on Earth, themselves serve
as natural dosimeters by absorbing and storing energy as trapped electrons. These
electron traps can then be emptied by heat or by exposure to photons of various
wavelengths, causing luminescence. The intensity of the emitted luminescence is in

Solid-state dosimetry: the basics

11

turn related to the growth of the absorbed dose. The fundamental assumption in
luminescence dating of sediments is that the minerals have been “bleached” prior to
burial: the charge traps have been emptied by sunlight and thus any record of
radiation exposure prior to burial has been erased [11].
The radiation energy absorbed by sediments is termed the “equivalent dose” (De),
because it accounts both for the amount and type of radiation absorbed by the
material.
2.2.2 Dose: medical physics
In medical physics, the concept of dose revolves around the biological effect that
radiation has on organs and tissues in the human body, rather than pure energy
deposition. The biological effect stems from the local rate of energy deposition along
the particle track and is influenced by the linear energy transfer (LET). Heavy
charged particles have a high LET, whereas the lighter electrons have a low LET:
thus the same dose will have a greater biological effect in the case of alpha particles,
as compared to electrons.
For uncharged particles (e.g., photons), this concept is further addressed by the
measurement of kerma, forming the basis of medical physics dose calculations.
Kerma is defined by the kinetic energy released per unit mass, and is approximately
equal to the absorbed dose for low energy photons, but is greater than the absorbed
dose in the case of higher energy photons, due to some of the particles escaping the
medium without being absorbed. Photons transfer their energy in a two-step
process:
1. Primary uncharged particles transfer energy to secondary charged
particles via the photoelectric effect, Compton scattering, or pair
production.
2. Secondary charged particles transfer energy to the medium via excitation
and ionization.
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Kerma is usually measured as air-kerma, and then related to absorbed dose by
accounting for the location of measurement, spatial distribution of radioactivity and
packaging of the radiation source, photon scattering and attenuation due to various
factors, and source anisotropy for the brachytherapy source addressed in this thesis.
The precise mode of dose calculation is addressed in Chapter 7.

Chapter 3
Part 1
Retrospective dosimetry: dating of geological
sediment
Accurate chronology is fundamental to the studies of archeology and geology. The
correct temporal placement of biological and cultural remains and geological
phenomena is essential in order to establish a timeline of events and piece together
the complex evolution of hominins, the nature of their societies and migration
patterns. Geological events, in turn, can further our knowledge on Earth’s structure
and evolution over time, and act as an aid in a multitude of related studies, including
human evolution and dispersal.

3.1

Luminescence dating

Luminescence dating has been widely employed for chronology of archeological and
geological materials [12-17]. Techniques such as thermoluminescence (TL),
optically stimulated luminescence (OSL), and infrared stimulated luminescence
(IRSL) are used to measure the luminescence signal of sediment. TL methods can be
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applied to both quartz and feldspar [11], whereas OSL methods focus on quartz
[18], and IRSL on feldspars [19]. Quartz is sensitive to wavelengths of blue/green
photons, and feldspar is especially sensitive to infrared photons [20]. These dating
methods can cover a wider range of ages than radiocarbon dating — from hundreds
to hundreds of thousands of years [21]. Techniques such as post-IR IRSL [22, 23],
violet stimulated luminescence (VSL) [24, 25] and thermally-transferred (TT) OSL
methods [26] can potentially extend up to 1 million years. Furthermore,
luminescence ages are derived directly in calendar years, without conversion
systems, such as that applicable to radiocarbon years. Dating is performed directly
on the mineral debris in sediments, as opposed to scarce organic materials. An
advantage of OSL over TL is the simplicity of the procedure, that among other
aspects, reduces the setbacks related to heating, such as alteration and oxidation of
the sample [27]. Moreover, the OSL signal is easier and more completely reset by
sunlight, than is the TL signal.
The luminescence age of sediment is calculated using two components: the
equivalent dose, De (sometimes referred to as the paleodose) and the environmental
dose rate, Dr, according to the following equation:
Age =

!!
!!

(3.1)

The equivalent dose is determined in Grays from the intensity of the OSL signal of
the sample, calibrated against the radiation dose given in the laboratory. Most
recently this has been done using the single-aliquot regenerative-dose (SAR)
technique, that takes account of sensitivity changes due to laboratory treatments of
the sample [27-29], as well as using single grains. A grain is the most fundamental
unit of analysis in sediment dating, and thus De evaluation at the level of individual
grains allows assessment of the distribution of the determined De values. Thus
grains with favorable luminescence properties can be selected, sufficient sample
bleaching prior to burial can be verified using statistical models, and outlier De
values resulting from insufficient bleaching or post-depositional mixing can be
rejected prior to age determination [27, 30-32].
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Environmental dose rate

The environmental dose rate quantifies the radioactivity of the sample and the
materials surrounding it. It is defined as the sum of the individual dose rate (D)
contributions from the alpha, beta, gamma, and cosmic ray particles that the
dosimeter grains are exposed to throughout their burial period. Environmental dose
rate contributors are primarily related to radioisotopes in the uranium and thorium
decay series and potassium (40K), that are naturally present in the environment,
along with the cosmic rays penetrating the Earth’s surface. The dose rate
component of the age equation is the focus of this thesis, and is expressed as
follows:
D! =
238U

D! , D! , D! , D!"#$%!

(3.2)

and 235U constitute natural uranium and occur in concentrations of 99.28% and

0.72%, respectively; both undergo alpha decay, and have respective half-lives of
4.47 x 109 y and 7.04 x 108 y. 232Th constitutes 99.98% of natural thorium, also
undergoes alpha decay, and has a half-life of 1.40 x 1010 y. 238U and 235U constitute
natural uranium and occur in concentrations of 99.28% and 0.72%, respectively;
both undergo alpha decay, and have respective half-lives of 4.47 x 109 y and 7.04 x
108 y. 232Th constitutes 99.98% of natural thorium, also undergoes alpha decay, and
has a half-life of 1.40 x 1010 y. Both the uranium and thorium series are
characterized by complex decay schemes, containing 18, 16, and 11 daughter
isotopes for 238U, 235U, and 232Th, respectively. 238U daughters include the elements
Th, Pa, Ra, Rn, Po, At, Pb, Bi, Tl, and Hg, ending in the stable 206Pb; 235U daughters
include the elements Th, Pa, Ac, Ra, Fr, At, Rn, Bi, Po, Pb, and Tl, ending in the stable
207Pb; 232Th

daughters include the elements Ra, Ac, Rn, Po, Pb, Bi, and Tl, ending in

the stable 206Pb.
40K

is the isotope of natural potassium that undergoes beta decay into stable 40Ca

and 40Ar with a half life of 1.25 x 109 y. 87Rb is the radioactive isotope of natural
rubidium that contributes a small proportion to the total dose rate (usually as an
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internal contributor to K-feldspar grain dose rates) via beta decay, with a half-life of
48.1 x 109 y. Equation 3.2 is disaggregated into its respective dose rate components
as follows:
!! : 238U and U, Th, Ra, Rn, Po, Bi daughter products; 235U and Pa, Ac, Th, Fr,
Ra, Rn, Po, Bi daughter products; 232Th and Th, Ra, Rn, Po, Bi daughter
products.
!! : 238U and U, Th, Pa, Ra, Pb, Bi daughter products; 235U and U, Pa, Ac, Th, Fr,
Ra, Rn, Bi, Pb, Tl daughter products; 232Th and Th, Ra, Ac, Pb, Bi, Tl daughter
products; 40K; 87Rb.
!! : 238U and U, Th, Pa, Ra, Pb, Bi daughter products; 235U and U, Pa, Ac, Th, Fr,
Ra, Rn, Bi, Pb, Tl daughter products; 232Th and Th, Ra, Rn, Ac, Pb, Bi, Tl
daughter products; 40K.
!!"#$%! : cosmic ray dose for muons (D0) is determined for x, a depth below
ground level, measured in hg/cm2. x can range from surface-level to 104
hg/cm2 of rock, at any altitude to 5 km. D0 is quantified as follows [33]:
!! =

!"#$
(!!!!.!)!.!" !!")(!!!"!)

exp (−5.50x10!! !)

(3.3)

Complete lists of the uranium and thorium decay series with their corresponding
energies and dose rates can be found in Adamiec and Aitken (1998) [34]. The
fundamental assumption is that the dose rate has been constant throughout the
sample’s burial period. Secular equilibrium (i.e. activity equilibrium of the parent
and daughters) is also often assumed when only the parental concentrations of U
and Th are measured (e.g., by inductively coupled plasma mass spectrometry). If
disequilibrium is present, then its effect should be estimated and corrected, when
necessary, using models such as those developed by Olley et al. (1996) [35, 36].
Moreover, water exhibits greater attenuating effects as compared to air, and thus its
presence in sample pores must also be considered.
Cosmic rays have the highest effect upon environmental dose rates in the top meter
of sediment. The range of alpha, beta, and gamma particles in sediment is much
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lower: ~0.03, 3, and 300 mm, respectively. While cosmic rays comprise just a small
fraction of the total dose rate, and U and Th are normally present in 1-10 ppm
concentrations, K accounts for 0.5 - 3% of the sample weight [37]. 40K typically
accounts for ~40-70% of the environmental dose rate, and up to 80% of the total
beta dose rate.
3.2.1

40K

beta dose rate

Beta dose rate can be measured either by quantifying the 40K concentration within
the sample, or by direct counting of the sample beta particles. The dose rate is then
estimated based on the infinite matrix assumption, postulating that the dose rate is
equal to the rate of energy emission per unit mass (Aitken, 1985). Dose rate
conversion factors have been determined using the data compiled in Evaluated
Nuclear Structure Data Files by the National Nuclear Data Center in the Brookhaven
National Laboratory, as reported in Table 3.1.
40K

Natural abundance (mg/g)
Beta Ē (MeV)
Gamma Ē (MeV)
Specific A (Bq/kg), 1% nat. K
β
γ
Dose rate at 1% (Gy/ka)
β
γ

0.119
0.499
0.1557
282.5
33.73
0.7982
0.2491

Table 3.1. 40K isotope data for each disintegration, and natural abundance of 116.7
ppm, modified from Guérin et al. (2011) [38].
40K

distribution within sediments may be inhomogenous due to the non-uniform

distribution of K-feldspar grains and the spatially variable presence of other Kbearing materials (such as hearth ash and phosphates). In single-grain OSL dating,
sand-sized grains (e.g., 180-212 µm in diameter) are routinely used, and thus small-
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scale beta variability can result in a large coefficient of variation in dose and dose
rate. Precise information on the location of the dose rate sources in relation to the
dated grains would therefore enable a more accurate estimate the environmental
dose rate. Moreover contextual information on the microstratigraphy of the sample
would allow the assessment of potential diagenesis and post-depositional
disturbances that may affect the distributions of measured doses and dose rates.
Beta dose rates are commonly measured on homogenized, bulk samples of much
greater sizes than the range of beta particles using techniques such as beta counting
or inductively coupled plasma mass spectrometry/optical emission spectroscopy
(ICP-MS/OES). These bulk-sample approaches may not be informative for individual
grain distributions [39]. To better interpret the dispersion of single-grain De values
and improve the accuracy and precision of ages obtained using single-grain OSL
dating, Dr values corresponding to the respective individual grain De values should
be obtained, to ultimately achieve “grain by grain” dating [20, 40].

3.3

Project aim

The aim of this study is to employ solid-state semiconductor dosimetry to develop a
method of deriving spatially resolved dose rates for intact sediment samples,
thereby preserving their microstratigraphic integrity and estimating dose rates at a
spatial resolution that accounts for the range of beta particles in sediment. This aim
was divided into three components:
1. Determine the feasibility of measuring dose rates in sediment using the
proposed detector.
2. Develop a measurement procedure and visualize radiation ‘cold’ and ‘hot’
spots within the samples; calibrate the detector in order to convert
measurement output to environmental dose rates.
3. Apply the developed method to determine spatially resolved dose rates for a
selection of real sediment samples.

Chapter 4
Radiation inhomogeneity in sediments
In single-grain OSL dating techniques, De values are often obtained from a small
proportion (e.g., 20% or less) of the measured grains following a meticulous
rejection process [27, 41, 42]. While strict selection criteria may be used for the
dosimeter grains, Dr measurements fail to deliver similar accuracy. The scatter in
the De distribution is directly affected by the radioemitter distribution within
samples, and hence, their Dr values. Grains located in close proximity to radioactive
sediment components such as K-feldspar, zircon, and monazite receive higher
amounts of dose, as compared to the grains positioned further away. Accounting for
the scatter in the dose rates, in addition to that of the equivalent doses, is especially
important due to the high radiation gradients within sediments.

4.1

Previous studies

Radiation inhomogeneity within samples has been addressed in previous studies
using both simulation and experimental methods. Simulation studies employ
modeling algorithms to quantify dose rate distributions, while experimental studies
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directly measure sample radioactivity, and have sometimes been applied in
combination with modeling techniques.
4.1.1 Simulation approach
Monte Carlo (MC) methods have commonly been utilized to expedite the long
measurement times required by experimental studies, as well as to achieve high
spatial accuracies. The MC radiation transport code enables the estimation of
accumulated doses in samples of various geometries, packing arrangements, and
elemental compositions. Complex distributions of dosimeter and source grains
within the sample can be achieved, and various radionuclide concentrations can be
assigned to the sources in order to emulate the real sediment context. Although
previous simulation studies involve simplifications of sample geometry by utilizing
approximations such as random grain packing [43] and pure statistical modeling
[44], they have demonstrated the importance of accounting for beta heterogeneities
in dose rate calculations. Geant4, a MC simulation toolkit developed by CERN [45,
46] allows higher levels of geometrical complexity, and has been incorporated into
the DosiVox modeling software customized for sediment applications [47]. DosiVox
provides a user-friendly interface for sediment dose modeling, allows different
levels of geometrical complexity, and has been shown especially useful in the cases
where the assumption of an infinite dose matrix is not applicable [47-49].
Other studies have used a combination of MC simulations and experimental
measurements to assess the influence of beta heterogeneity. Nathan et al. (2003)
[50] and Cunningham et al. (2012) [51] have used Monte Carlo N-Particle (MCNP)
Transport Code in combination with physical α-Al2O3: C grain measurements,
concluding that beta heterogeneity affects the distribution of in single grain De
values. Both cases, however, were lacking in agreement between experimental and
simulation results. Moreover, in the case of Cunningham et al. the experimental
component involved neutron bombardment of the sample to achieve sufficient
irradiation of the dosimeter grains within the two-week timeframe of measurement.
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4.1.2 Experimental approach
Experimental measurements of spatially resolved dose rates in sediments constitute
a challenge due to the inherently low levels of activity in natural samples. High
detector sensitivity and effective background suppression are imperative to enable
sample measurement at the desired spatial resolution. Moreover, detector stability
over long measurement periods is essential; these can range from days to months.
Previous studies have developed methods to visualize and quantify dose rate
dispersion in sediments, employing techniques such as autoradiography, α-Al2O3: C
grains, and fission tracks. Autoradiography methods have been successful in the
visualization of the radioactivity within geological samples, allowing samples in
various forms to be placed directly on the imaging plate to measure the intensity of
the emitted radiation signal [52]. These studies have also found that the
autoradiography detection limit is reached for some low-activity environmental
samples [53]. α-Al2O3: C grains of 200-300 μm diameter have been mixed with
sediments to quantify dose rate distributions using the SAR protocol, successfully
measuring the Dr distribution and attributing a relative uncertainty of 18% to Dr
inhomogeneity [54]. The fission track method employed for spatially resolved dose
rate determination in U and Th isotopes allows a 20 μm spatial resolution; dose
rates are estimated via measurement of fission track densities following neutron
bombardment [55].
Other studies have employed X-ray spectroscopy [56], X-ray computed
microtomography [57], and CCD imaging [58] for the visualization of potassium
feldspars within sediments. These studies have further highlighted the possible
deviations from the mean beta dose rate values, and the significance of highly
concentrated radiation emitters in close proximity to dosimeter grains. Laser
Ablation Inductively-Coupled Plasma Mass Spectrometry (LA-ICP-MS) has also been
used to visualize and quantify concentrations of radioemitters [59].

Radiation inhomogeneity in sediments

22

4.2 Visualization of radiation hotspots using the Timepix detector
Solid-state dosimetry has not been extended to sediment measurements, primarily
due to the low activity of sediment samples and, thus, the inability to discriminate
sample emissions from the background noise. This study employs a highly sensitive
pixelated semiconductor detector, the Timepix, to visualize radiation hotspots
within sediment samples.

4.2.1 The Timepix
The Timepix is a hybrid-pixel detector that contains a 300-μm high-resistivity
silicon sensor that is bump-bonded using Flip Chip® [60] technologies (Fig. 4.1).
The sensor area is 1.98 cm2 and contains a 256 x 256 array of 55 x 55 μm2 pixels.
Each pixel has to its own 14-bit counter, threshold discriminator, and preamplifier,
and contains 65,536 independent readout channels, providing excellent spatial
resolution [61]. It was developed by the Medipix2 collaboration, incorporating the
Timepix readout chip into the conventional event-counter chip, enabling energy
deposition measurement in the “time-over-threshold” mode. For energy
measurement, the counter is incremented continuously during the period of time
that the preamplifier output charge exceeds the threshold [62].

Figure 4.1 Timepix chip.
The detector is able to recognize particle types such as alphas, betas, gammas, and
cosmic rays based on their energy deposition and morphology of their tracks [63].
Each particle is characterized by the shape of the cluster that it creates in the
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detector pixels while depositing its energy in the silicon chip, which varies
depending on the particle charge, velocity, mass, and angle of incidence. An incident
particle deposits its charge by interacting with the silicon sensor, and electronic
transport of the particle charge to the pixel preamplifiers results in a signal. Charged
particles interact with electrons in the silicon, which can result in strong collisions
in the case of beta particles, creating winding tracks within the detector, or create
secondary short ranged electrons that deposit their energy quickly and involve
nearer pixels, such as alpha particles. Energetic beta particles leave long, curly
tracks (figures 4.2a,b,c), while less energetic betas of < 100 keV produce single,
double, triple, and quadruple hits. Gamma particles deposit their energy indirectly
through electrons, and thus their track shapes resemble those of the less energetic
beta particles. Alpha particles are heavier and deposit their energy in the form of
blobs (figure 4.2d).

Figure 4.2 Cluster shapes of beta particle tracks (a, b, c) and a heavy blob
characteristic of alpha particles (d).
Timepix operates on a frame-by-frame basis: a digital shutter opens and closes, after
which the data collected in the pixels is read out. Frame length must be long enough
for registered particle tracks to not overlap, and short enough to reduce the total
number of frames and, thus, analysis time and data storage. It is set by the user and
can be as short as 80 frames per second. Pixelman readout software is used for

Radiation inhomogeneity in sediments

24

measurement acquisition, allowing the user to select measurement settings such as
the frame length, time of acquisition, measurement threshold, and the file type
where the acquisition is stored [64]. The frame-by-frame visualization is displayed
on the screen, where the individual particles detected are displayed as a heatmap of
their energy deposition in each pixel (figure 4.3).

Figure 4.3 Example of output display using Pixelman software.
Individual frames are stored as 256 x 256 matrices, containing energy deposition or
count data for each pixel. The Jablotron MX-10 Timepix chip used in this study is
pre-calibrated, with linear parameters a and b, and non-linear parameters c and t,
used to convert each TOT frame into pixel-by-pixel energies as follows:

Radiation inhomogeneity in sediments
!"! = ! + !" +

25
!
!−!

(4.1)

where TOT is the time-over-threshold response of the detector (ns), and E is
the input energy (keV).
Energy calibration can be carried out assuming that all pixels have a uniform
response, or by compensating for the differences in pixel response (i.e., an inherent
property of the detector). Energy calibration is typically performed using four
spectral lines: the 5.9 keV peak from 55Fe, 59.5 keV peak from 241Am, and two
additional from X-ray fluorescence lines. The TOT value of single pixel hits is
measured and fit to the most likely value of the spectrum, corresponding to pixel
energy [65].
In order to ensure a uniform response among pixels a threshold equalization
procedure is carried out with a fixed energy setting to align pixel thresholds using
the background noise. This can be done either using the “noise edge”, where noise is
defined by pixels exceeding a certain noise value, or using the “centroid” method,
where the center of the noise is determined using a Gaussian distribution. The latter
method is recommended to better accommodate the pixel-to-pixel response
variation over the entire chip. More details on this procedure can be found in [65].
DAC settings established during the centroid threshold equalization procedure are
shown at the bottom of figure 4.3. This procedure also masks any existing dead
pixels to prevent consistent over-response.
The acquired measurement frames are then run through cluster analysis, based on
the Medipix Analysis Framework (MAFalda) that groups registered pixel hits into
clusters [66]. The clusters are characterized according to a number of parameters,
including the total number of pixels and inner pixels in each cluster, cluster TOT,
energy, x and y centroids, length in the x-y directions, type, and the time of cluster
registration. A “minimum bounding box” is drawn for each cluster, and used to
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determine the length, width, x-y dimensions, and density. Clusters are then
attributed to one of the six geometric types, characterizing the physics of the
particle, as defined by the Institute for Advanced Experimental Physics at the Czech
Technical Institute in Prague: small blob, medium blob, heavy track, heavy blob,
straight track, and light track [63]. They are distinguished according to the cluster
number of inner pixels, length/width ratio, and additional criteria (i.e., a light track
is not straight, density value, total number of pixels). Beta particles are attributed to
light tracks.
4.2.2 Background suppression
A 3 cm-thick lead container capable of enclosing the Timepix detector was used for
all sediment measurements. The interior walls of the container were lined with a
thin layer of aluminum to absorb backscattering. Measurement setup is shown in
figure 4.4, with the Timepix positioned inside the lead box and connected to a laptop
with Pixelman software. Figure 4.4b shows a sample placed over the Timepix sensor
inside the lead container.

Figure 4.4 Measurement setup with the lead container (a) and sample placed over
the Timepix for measurement (b).
Cosmic rays are characterized by particularly high energies and are able to
penetrate through the lead shielding, but they also deposit their energy in particular
energetic tracks in the silicon chip of the Timepix. Following measurement and
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cluster analysis of the acquired frames, they were eliminated from sample analysis
along with other heavy particle tracks, while curly electron tracks of > 100 keV,
mostly pertaining to the 40K betas, were selected for sample evaluation.
4.2.3 Initial feasibility studies
The aim of this study was to test the feasibility of radioactivity visualization in
geological samples using the Timepix detector, starting with samples of high activity
and progressing to samples of lower activity, which are more representative of
sediment samples from the field.
4.2.3.1

High activity samples

The first geological sample selected for measurement on the Timepix was biotite,
chosen due to its high 40K content and, thus, naturally high levels of beta activity. A
13 x 18 x 3 mm3 slice of the dark mica material was placed on the plastic exterior of
the Timepix, about 2 mm above the detector sensor, covering approximately half of
the chip (figure 4.4b). The measurement was acquired using the integral frame
measurement setting, to test the ability of visualizing the region of the chip occupied
by the radioactive material. A 2D 256 x 256 pixel hitmap of the preliminary
measurement is shown in figure 4.5a, where the portion of the Timepix chip
occupied by the biotite slice is clearly visible on the bottom half of the hitmap. The
hitmap scale corresponds to the number of counts. The total counts acquired during
the measurement in the Y pixel of the sensor are shown in Fig. 4.5b on a onedimensional hitmap, demonstrating a range of 1200-1800 counts in the biotite
region, and a range of 450-1100 counts for the region containing no sample, with
the higher counts of the latter range attributed to scattering from the sample.

Radiation inhomogeneity in sediments

28

Figure 4.5 2D (a) and 1D (b) hitmaps of the biotite slice measurement.
The next sample was produced to represent a sediment sample with cold-spots and
radioactive hot-spots distributed inside (figure 4.6a). Biotite spheres were
embedded in a block of resin and measured on the Timepix for 6 days. The 2D pixelby-pixel hitmap is shown in figure 4.6b, with the eight biotite spheres clearly
visualized, containing ~3 times the number of counts as compared to the resin
region of the sample.

Figure 4.6 Biotite spheres embedded in resin (a) and the corresponding Timepix 2D
hitmap of sample counts (b).
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The next artificial sample was produced using biotite, quartz, and monazite grains,
again held together by resin. Monazite was selected as an additional high-activity
natural mineral containing high concentrations of thorium. The results of the 5-day
measurement are shown on the 2D hitmap in figure 4.7. Monazite proved to be even
more radioactive than biotite, completely overpowering the biotite emissions, and
replicating the shape of the monazite sample component in its count distribution.

Figure 4.7 Quartz (light brown), biotite (black), and monazite (dark brown) sample
(a) and the Timepix 2D hitmap of counts (b).
Thus, high activity geological materials were successfully visualized by the spatially
resolved Timepix count distribution. The next step was to assess the detector’s
ability to detect significantly lower concentrations of radioactive materials in
natural and artificially produced samples.
4.2.3.2

Lower activity samples

Diorite was selected due to its variety of 40K radioemitters, including feldspar and
biotite. The sample (figure 4.8a) was cut from a rock and not prepared in any other
way (e.g., crushing, powdering or impregnating in resin). It was then measured for
11 days, and an average count rate of 2.58 counts/min was determined.
Measurement frames were analyzed with cluster analysis, and alpha and beta tracks
were selected to visualize the radiation distribution in the sample. The
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corresponding 2D hitmap is shown in figure 4.8b, where the radiation hot-spots are
shown as increased count regions.

Figure 4.8 Diorite sample (a) and the corresponding 2D hitmap of counts (b).
An artificial sample was also fabricated to provide an appropriate model of a
sediment sample. 200-300 μm diameter grains of natural feldspar and purified
quartz were uniformly mixed in respective concentrations of 7 and 93%, and
solidified using epoxy resin (figure 4.9a). The sample was measured on the Timepix
for 21 days, and subjected to cluster analysis selecting electron tracks, arriving at a
total dose rate of 2.36 counts/min. The resulting 2D hitmap of these particle tracks
is shown in figure 4.9b. A few radiation hotspots are visible, despite attempted
uniform mixing of the sample, demonstrating the high spatial resolution of the
Timepix.
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Figure 4.9 Custom sample composed of 7% feldspar and 93% quartz (a) and the
corresponding 2D hitmap of counts (b).
These measurements served as preliminary estimates of the measurement time
required to obtain radioisotope visualization for high- and low-activity sediments.
As a result, measurement time was estimated to lie in the range of 4 days to one
month, depending on the radionuclide concentrations of the particular sample.
Importantly, the Timepix showed a stable response over the 21-day measurement
period.

4.3 Conclusions
Previous studies have highlighted the need for further development of experimental
methods to quantify spatially resolved dose rates in sediment samples, as discussed
in section 4.1.
The challenge of minimizing background noise for sediment sample measurement
on the Timepix has been addressed through a combination of physical shielding and
post-acquisition data analysis. Lead shielding resulted in a noise reduction of more
than 50%. Background particles of uncharacteristically low and high energies in the
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context of the expected 40K emissions could be discriminated using cluster analysis,
allowing for the sole analysis of beta tracks deposited in the detector.
Preliminary feasibility studies employing real and artificial samples of high and
lower radiation activity demonstrated the ability of the Timepix to visualize
radiation hotspots within samples and the potential to derive spatially resolved beta
dose rates for natural sediment samples.

Chapter 5
Spatially resolved dose rates in sediment
samples: development of method
5.1

Aim of this chapter

Following the preliminary feasibility studies described in the previous chapter, the
next step was to develop a procedure for Timepix sediment measurements and
establish a calibration to convert the measured count rates in silicon to dose rates in
sediment.
This involved both MC simulations and experimental methods. Both relative and
absolute dose rate calibration functions were derived, beginning with the former
and concluding with the latter, and thus minimizing dose conversion uncertainties.

5.2

Geant4 simulation component

MC simulations were used to facilitate Timepix method development, addressing
both the measurement procedure and data analysis. Experimental setup was
simulated by modeling the Timepix sensor as a 14 x 14 x 0.3 mm3 silicon box with
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an overlaid grid containing a 256 x 256 voxelized readout geometry, emulating
individual pixels of the Timepix. Energy deposition in each voxel and its
corresponding x-y coordinates were scored for each incident particle, and reported
in the simulation output file. Geant4 version 10.1 with EmStandardPhysics_option3
for particle electromagnetic interactions and Geant4 Radioactive Decay Model were
included in the Physics List. The sample was modeled as a 10 x 10 mm2 piece of SiO2
containing a uniform distribution of 40K.
The first simulation serving as validation for the geometry and

40K

decay was a

reproduction of the biotite study described in section 4.2.3.1. The results of the 1week measurement simulation are shown in figure 5.1, with the number of particles
per unit energy (keV) plotted as a function of the energy deposition in the Timepix.
The experimental results, shown in black, demonstrated good agreement with the
simulation results, shown in red. A minor discrepancy between the two in the lower
energy region (< 50 keV) is explained by the lack of background noise in the Geant4
environment.

Figure 5.1 Experimental and Geant4 simulation results for the biotite sample
measurement on the Timepix detector.
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Geant4 simulations were then used to determine optimal sample-to-detector
distance and sample thickness, as well as to derive an edge correction for pixels
located close to the sample edge.
5.2.1 Sample-to-detector distance
To determine optimal placement of the sample with respect to the detector sensor,
the biotite sample distance from the detector chip was varied between 0 and 10 mm
in the simulation geometry. Counts detected in the silicon detector chip were
evaluated for each of the 10, 7.5, 5, 4, 3, 2, 1, and 0 mm biotite distances from the
detector. Figure 5.2 shows the counts detected by the Timepix as a function of the
sample position on the sensor for all sample-to-detector distances.

Figure 5.2 Timepix counts as a function of sample position on the Timepix for a
range of source-to-detector distances.
These results show that decreasing the sample-to-detector distance from the 2 mm
position used in the biotite study to 0 mm resulted in a 25% increase in detected
counts. Thus, to maximize sample counts, the sample should be placed directly on
the detector sensor.
5.2.2 Sample thickness
Simulation geometry was modified to correspond to sample placement in the center
of the Timepix sensitive area, and simulations were run to evaluate the effect of
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increasing sample thickness. The schematic of the simulation geometry is shown in
figure 5.3a, where the gray slab represents the Timepix silicon sensor, and the
orange cube represents the SiO2 sample. Figure 5.3b shows the beta (white) and
gamma (green) particles resulting from the uniform 40K decay within a 10 mm-thick
sample, outlined in red, that are incident on the yellow Timepix sensor.

Figure 5.3 Schematic of the Geant4 simulation geometry, where the gray slab
represents the Timepix silicon sensor, and the orange cube represents the SiO2
sample (a), and the uniform emission of the 40K decay particles arising from the
sample (b).
The z-dimension of the SiO2 sample was modified between simulation runs to test
thicknesses of 0.1, 1-10, 15, 20, and 30 mm. The results of these simulations are
shown in figure 5.4. A plateau in the detected counts per pixel resulted at
thicknesses of ≥ 3 mm, similar to the known range of beta particles in sediment.
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Figure 5.4 Clusters/pixel detected by the Timepix as a function of sample thickness.
This plateau is explained by beta absorption inside the sample, from which it was
concluded that sample thickness should be kept at 3 mm to maximize detected
counts and optimally visualize the radioemitter distribution within the sample.
5.2.3 Edge correction
When a sample of finite size is placed on the detector sensor (which is also of finite
size), a decrease in sample emissions incident on the detector is observed close to
the sample edge, due to the lack of 2π geometry of emissions. An edge correction
was derived as a function of pixel proximity to sample edge, utilizing the spatially
resolved Geant4 simulation results of a 3 mm-thick sample positioned on the
Timepix sensor. The simulation output matrix of the scored particle positions was
converted into a binary matrix, where the pixels below the sample area were
assigned a value of 1 and pixels outside this area were assigned a value of 0. Pixels
were grouped into clusters, and the proximity of each cluster to the sample edge
was defined by the sum of the binary matrix, weighted by a Gaussian kernel. Higher
pixel values indicated proximity to the center of the sample, while lower values
indicated proximity to the edge. Normalized counts as a function of pixel proximity
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to sample edge, defined in arbitrary units and normalized to unity at the sample
center, are plotted in figure 5.5.

Figure 5.5 Edge correction function (arbitrary units).
These results were then fitted with a polynomial function, f (i.e., the correction
factor that defines the degree of count adjustment based on the fraction of detected
counts in relationship to the detection rate at the center of the sample), determined
as follows:
! ! = −2.3875! ! + 4.1156! ! − 1.0169! + 0.2888

(5.1)

Each pixel underneath the sample must be defined in terms of its proximity to the
edge of the sample, d. Its corresponding count rate is then adjusted by multiplying
the measured counts by 1/f.
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Sample preparation and measurement setup

There are two main requirements for geological sample measurement on the
Timepix: they must be consolidated to prevent potential damage to the highly
sensitive detector window, and sufficiently small for direct placement on the sensor.
5.3.1 Sample preparation
Geological samples were impregnated with epoxy resin for sample consolidation
according to the method of geoscience sample mounting applied in the University of
Wollongong (UOW) micromorphology laboratory [67]. A plaster mold was used to
encase the sample, placed inside a vessel, and epoxy resin was poured around it to
allow sample uptake of the resin via capillary action. A 7:3 proportion of resin and
styrene, respectively, were combined, and MEKP catalyst was added to allow the
mixture to harden. Once the sample was completely dry, it was cut into 10 x 10 x 6
mm3 subsamples using an IsoMet low-speed cutting machine for measurement on
the Timepix. Both sides of the sample were then measured.
5.3.2 Measurement setup
A thin strip of mylar film was placed between the detector sensor and the sample to
provide protection against scrapes (the beta particle range was unaffected).
Measurement setup is shown in figure 5.6a with a sample positioned over mylar
film on top of the Timepix sensor.
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Figure 5.6 (a) Timepix detector with a sample placed over mylar film. (b) Alpha
particle outline of the sample position on the detector’s sensitive chip.
Once the sample had been placed for measurement, an outline of its position was
created using an alpha 241Am source. The boundaries of the sample area were
delineated by holding the source above the measurement setup for a sufficient
amount of time to produce a precise outline of the sample shape on an integral
measurement frame displayed in the Pixelman software (figure 5.6b).

5.4

Dose rate calibration

The following sub-sections describe the methodology used to derive a calibration
curve to convert the Timepix count rate (counts/pixel) into environmental dose rate
(Gy/ka), applying both relative and absolute methods.
5.4.1 Relative calibration
A relative calibration was derived by measuring custom-made calibration samples
of varying radioactivity concentrations on the pre-calibrated beta counter and the
Timepix detector, and then relating the beta counter dose rates to the Timepix count
rates.
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Sample preparation

Two geological minerals, biotite and quartz, were selected for the radioactive and
nonradioactive components, respectively. Biotite was selected as an easily
obtainable mineral containing a high concentration of 40K. Quartz was extracted
from purified sand that has been treated with hydrofluoric acid to dispose of organic
materials, carbonates and feldspars, and then subjected to solutions of hydrogen
peroxide, hydrochloric acid and heavy mineral separation. The grain diameter range
was selected as approximately 200-350 μm to keep the grains uniform for
homogenous mixing. A total of five calibration samples were created containing
approximately 100, 80, 60, 40, and 20% biotite content by mass, with the rest of the
sample occupied by the nonradioactive quartz. Timepix samples were prepared as
described in section 5.2.1.
Beta counter samples were crushed and left for two weeks prior to measurement to
allow for secular equilibrium of radon and its daughter products. The samples were
not consolidated, to comply with the powder form of the beta counter calibration
source used to quantifying the beta environmental dose rate.
5.4.1.2

Beta counter measurement

A Risø GM-25-5 beta counter was used to quantify the beta dose rate in Gy/ka. The
instrument consists of a gas flow counter (99% argon, 1% butane) with five GeigerMueller (GM) tubes and a common guard counter [68, 69]. The beta counter is
housed inside a 10 cm-thick Pb bunker to reduce background interactions. A sample
of Nussloch Loess (Nussi) that had been measured previously by high-resolution
gamma spectrometry, and for which the dose rate is well-established [70], was used
for the beta dose-rate calibration [71].
Five 25 mm-diameter cylindrical pots were positioned on a sliding vessel to ensure
setup reproducibility. Three of the pots were filled with the powdered sample, one
with the powdered Nussi reference standard, and one with MgO as background. The
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measurement was run for 24 hours using 1-hour cycles that simultaneously
measure the 5 samples.
To convert the measured count rate into dose rate, the three replicate sample
measurements were averaged and compared against Nussi, following subtraction of
the background count rate. The dose rate was then determined using previously
established conversion factors [38]. The errors associated with the final dose rate
are quantified as the counting statistics of each sample, combined in quadrature,
and other instrumental reproducibility uncertainties (e.g., varying efficiencies of the
GM tubes), as detailed in Jacobs and Roberts (2015) [71]. The dose rate error of the
Nussi standard has been quantified at 1.8% from the concentration uncertainties of
U, Th, and K [70].
5.4.1.3

Results

The post-cluster analysis beta particle count rates calculated for the uniform
(central) region of the sample on the Timepix detector for the five calibration
samples are plotted against the corresponding dose rates measured using the beta
counter in figure 5.7. A calibration curve was derived to convert the Timepixmeasured count rate into beta dose rate:
Dr = 7E+06 * CTpx – 5.499

(5.2)

where Dr is the beta dose rate (in Gy/ka) and CTpx is the count rate measured
using the Timepix detector (counts/s/pixel).

Development of method

43

Figure 5.7 Timepix count rate to beta counter dose rate calibration curve. Errors are
shown at 1σ.
5.4.1.4

Discussion

Calibration samples were assumed to contain a uniform distribution of biotite and
quartz minerals with resin occupying only the pore spaces between the grains. The
linearity of the calibration function (figure 5.7) would appear to justify this
assumption.
Measurement uncertainties are attributed to errors associated with the Timepix
detector and beta counter. Beta-counter errors have been quantified by Jacobs and
Roberts (2015) [71]. Random errors include those arising from instrument
fluctuations, reproducibility among replicates, counting statistics, and variation in
the MgO background. Systematic errors associated with the beta counter are
estimated at ~1.8% for the Nussi reference standard and ~2% for the dose rate
conversion factors of Guerin et al. (2011) [38].
The Timepix count rate error was estimated by assuming a Poisson distribution, and
calculated as the square root of the total number of detected counts. The average
relative error associated with converting the Timepix count rate to beta dose rate
(using figure 5.7) was calculated as 3.16% for the beta counter and 1.50% for the
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Timepix detector, which gives a total relative error on the calibration curve of
3.50% for the total Timepix measurement area (all errors at 1σ). The error arising
from the conversion to Gy/ka is both small and systematic between pixels.
Although this calibration method is acceptable, beta-counter samples were placed in
plastic pods in powder form, whereas Timepix samples were fabricated using intact
grains embedded in resin, thus relating a higher dose rate to a lower one. Moreover,
a relative calibration method combines the errors of the two dose rate methods,
increasing the total calibration curve uncertainty.
5.4.2 Absolute calibration
5.4.2.1

Materials and methods

IAEA standard materials of IAEA-RGK-1, IAEA-RGTh-1, and IAEA-RGU-1, were
obtained for Timepix calibration of potassium, thorium, and uranium dose rates,
respectively. The potassium standard was produced from 99.8% potassium
sulphate, while the uranium and thorium standards were produced by the dilution
of uranium and thorium ores containing respective concentrations of 7.1% and
2.9%, mixed with floated silica powder, and verified for sample homogeneity and
radionuclide equilibrium by the supplier.
Three samples of varying isotope concentrations were prepared using MgO material
for radioisotope dilution. Potassium samples contained 100, 24, and 8%
concentrations of RGK-1 by mass, with corresponding dose rates of 39.6, 9.6, and 3.0
Gy/ka, respectively. Thorium samples contained 100, 49, and 12% concentrations of
RGTh-1, with corresponding dose rates of 22.2, 10.9, and 2.7 Gy/ka, respectively.
Uranium samples contained 100, 23, and 5% concentrations of RGU-1, with
corresponding dose rates of 55.3, 12.7, and 2.7 Gy/ka, respectively. The dose rates
were estimated using the conversion factors of Guérin et al. (2011) [38].
All samples were produced as described in section 5.2.1 and measured for 3-4 days
to obtain adequate statistics of the registered counts. Post-cluster analysis beta
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particle emission rates were then evaluated. Background counts were measured
using a small block of resin for a 3-week count acquisition on the Timepix chip.
5.4.2.2

Results

Three calibration functions were derived for the three isotopes, relating Timepix
count rate (counts/pixel/second) to environmental dose rate (Gy/ka/pixel). The
background-adjusted calibration functions are plotted in figure 5.8, and were
derived as follows:
Dr (K) = 2.9E+06 * CTpx

(5.3)

Dr (Th) = 3.6E+06x * CTpx

(5.4)

Dr (U) = 3.3E+06x * CTpx

(5.5)

Figure 5.8 Timepix absolute calibration results for K, Th, and U dose rates.
The error bars in figure 5.8 reflect the error on the pixel (i.e., 55 x 55 μm2) spatial
resolution and are shown at 1σ. The corresponding R2 values of the linear fit are
0.998, 0.999, and 0.997 for K, Th, and U, respectively.
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Discussion

Calibration count rate errors for each 55 x 55 μm2 pixel are 24.3%, 22.2% and
35.4%, for K, U and Th, respectively, decreasing to 5.7%, 7.4% and 11.8% at a 1 mm2
resolution (i.e., containing counts for 18 x 18 adjacent pixels). The relative standard
uncertainty of the IAEA standard is quantified as 2.86%, yielding total uncertainties
(at 1σ) of 5.7%, 5.2% and 8.3% for the potassium, uranium and thorium dose rates,
respectively, at the 1 mm2 spatial resolution.
The spatially resolved Timepix beta particle count rate in counts/pixel/second can
be converted into an environmental dose rate at the desired spatial resolution using
the determined count rate-to-dose rate relationship. All three curves are based on
the beta particle dose rate, which is more relevant for dating than the dose rate due
to alpha particles, which are also prominent in the uranium and thorium
radionuclides, but which have a much shorter range and are commonly removed as
a dose-rate contributor by acid-etching of sand-sized grains prior to De
measurement.

5.5

Sediment dose rate measurement: procedure outline

Following the Geant4 simulation and experimental method development described
in sections 5.2 - 5.4, a procedure was established for sediment dose rate
measurement with the Timepix, as outlined below:
1. Sample of sediment is resinated and cut to obtain a consolidated sample of
10 x 10 x 6 mm3 dimensions.
2. Sample is placed on the Timepix sensor, separated by mylar film.
3. Sample position on the sensor is delineated using an 241Am source on an
integral measurement frame.
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4. Measurement is acquired using efficient frame lengths and ensuring
adequate counting statistics for dose rate derivation. Measurement length
can range from days to more than one month.
5. Cluster analysis of the acquired frames is performed and measurement
frames are integrated into one hitmap.
6. Beta particles are selected and adjusted for background noise.
7. Pixels outside the sample area are excluded, using the 241Am source
delineation.
8. Edge correction is applied.
9. Pixels are binned into sub-millimeter regions to reduce the counting errors.
10. Spatially resolved beta particle dose rates are derived using the applicable
calibration curve for K, U, and Th.

Chapter 6
Spatially resolved dose rates in sediment
samples: application of method
6.1

Aim of this chapter

The aim of this chapter is to apply the developed Timepix methodology to
determine dose rates in sediments. First we examine an artificial sample, followed
by field samples from two cave sites of high archeological significance: Liang Bua in
Flores, Indonesia and Denisova in southern Siberia, Russia.

6.2

Artificial sample

Spatially resolved sediment dose rates were first determined for an artificial sample
with visible stratification of known radioactive and nonradioactive components.
6.2.1 Materials and methods
A micro-stratified sample was prepared as per Timepix sample preparation
procedure (section 5.3.1), using 200–350 μm-diameter grains of quartz and biotite.
The sample was chosen as a simplified representation of a real sediment sample,
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with dose rates previously quantified using the beta counter. The sample is shown
in figure 5.1b, where the dark layers correspond to the radioactive biotite, and the
light layers to the non-radioactive quartz. The sample was measured on the Timepix
for a period of 7 days.
6.2.2 Results
Spatially resolved count rates at 0.1 mm resolution (i.e., cumulative counts for 2x2
pixels) are shown on a 2D hit map in figure 6.1a, with the scale on the right
corresponding to the number of counts per pixel cluster (c/p). The two sample
components are clearly visible based on their count rates, plotted as the x-y
centroids of the detected beta particles. The count rates of the biotite and quartz
regions are in the range of 25-60 and 0-25 counts/pixel cluster, respectively.

Figure 6.1 Artificial sample results: total number of counts per pixel cluster (a),
photo of micro-stratified sample (b), derived dose rate distribution within the
sample (c).
The corresponding spatially resolved dose rates in Gy/ka are shown in figure 6.1c at
a resolution of 0.88 x 0.88 mm2 (16x16 pixels).

40K

dose rates were determined

using the absolute potassium calibration curve, and range between -0.16 and 3.57
Gy/ka. The dose rates attributed to the biotite regions of the sample range between
0.82 and 3.57 Gy/ka, whereas the dose rates in the quartz region are distributed
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around a dose of 0.05 Gy/ka. The dose rates of the x and y pixel profiles are plotted
in figure 5.2, where the x-profile corresponds only to quartz, and the y-profile
captures both quartz and biotite, as shown in the figure 6.2 inset photo.

Figure 6.2 X and y dose rate profiles of the artificial sample. Error bars are shown at
1σ.
6.2.3 Discussion
Relative uncertainties (at 1σ) of 19.8 and 30.3% were determined for beta dose
rates of 3.5 and 1 Gy/ka, respectively, at a spatial resolution of 0.77 mm2, assuming
14 days of measurement time.
Because of Poisson statistics pertinent to Timepix count rates, some negative dose
rate values resulted following background adjustment. Dose rates below 0 were
found in regions of low count rates and are, therefore, considered to be statistically
insignificant. This is further demonstrated by the error bars on the x-profile in
figure 6.2, which show that negative dose values are consistent with statistical
uncertainty. It is possible to eliminate negative dose rate values altogether, either by
increasing measurement time or decreasing the spatial resolution.
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6.2.4 Conclusion
A spatially resolved beta dose rate distribution has been determined for an artificial
sample with a simplified

40K

distribution, utilizing the Timepix count rate

measurement and dose rate conversion procedure outlined in chapter 5. The ability
to quantify the beta-particle dose rate distribution using the proposed method has
been demonstrated with sub-millimeter spatial resolution.

6.3

Samples from Liang Bua and Denisova Cave

Liang Bua and Denisova Cave are both sites where archaic hominins have been
discovered in recent decades: the Homo floresiensis at Liang Bua, located on the
eastern Indonesian island of Flores [72-74], and Denisovans and Neanderthals at
Denisova Cave, located in the Altai Mountains of southern Siberia, Russia [4, 75, 76].
Robust dating methods are necessary to establish a reliable timeline for these
archaic hominin populations and to gain further understanding on the possible
interactions of these hominins with modern humans (Homo sapiens).
6.3.1 Materials and methods
The deposits in Liang Bua and Denisova Cave are characterized by variable
compositions and textures, thus allowing a broad range of sample types to be
measured on the Timepix. Liang Bua is located close to the equator in Indonesia and
is characterized by a warm climate with chemical alterations of the sediment after
deposition. Denisova Cave is situated in a colder region, the Altai Mountains in
Russia, so the original sedimentary context is better preserved as the deposits have
experienced fewer chemical modifications throughout the burial period.
A profile sample measuring 10 x 50 x 6 mm3 was obtained from each of these sites
and separated into five 10 x 10 x 6 mm3 sub-samples to accommodate the Timepix
detector. The Liang Bua sample was collected from Sector XXIV, straddling layers 8
and 9, and is composed of cave earth, limestone, manganese, and calcium carbonate.
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The Denisova Cave sample was collected from the Main Chamber, straddling layers
21 and 20, and contains regions of limestone, fine-grained silts and clays, phosphate
minerals, and fragments of bone.
Both sides of each 10 x 10 mm2 surface were measured for 4-19 days per side,
depending on sample activity. 40K dose rates were determined using the 40K
absolute calibration function (equation 5.3). Example results of the multiple phases
of data analysis are shown in figure 6.3: Liang Bua sample b (LB,b) is pictured in
figure 6.3a; figure 6.3b displays the raw hitmap of the total count rate of the LB,b
measurement, and figure 6.3c shows the resulting spatially resolved dose rates
following the selection of the area occupied by the sample on the detector sensor
and the conversion of count rate to environmental dose rate (Gy/ka). Figure 6.3c is
the final spatially resolved distribution of beta dose rates within this sample after
edge correction, which elevates the dose rates closer to the sample edge.

Figure 6.3 Data analysis process of Liang Bua sample b (LB,b) shown in (a): 2D
count rate hitmap (total counts/pixel) (b), result after application of the dose rate
calibration (Gy/ka) (c), and (d) result after application of the edge correction
(Gy/ka).
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6.3.2 Results and discussion
The Liang Bua and Denisova Cave sample profiles and their 2D dose rate maps, are
shown in figures 6.4 and 6.5, respectively. In each of these figures, the first two
columns on the left correspond to the front side of the sample, and the second two
columns correspond to the back of the sample. In the Liang Bua profile, the beta
dose rates range between 0 and 4 Gy/ka, with a mean value of 0.71 Gy/ka. In the
Denisova Cave sample profile, the dose rate ranges between 0 and 5.4 Gy/ka, with a
mean beta dose rate of 1.65 Gy/ka. The dose rate scale in both of the figures was
chosen for optimal visualization of the beta dose rate distribution.

Figure 6.4 Spatially resolved beta dose rates in the Liang Bua sample profile. Each
sub-sample is 10x10x6 mm3 in size.
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Although the range in dose rate of the two samples is relatively similar, the Denisova
Cave profile has a mean dose rate 2.3 times higher than that of the Liang Bua
sample. This difference can also be seen on the 2D dose rate hit maps of the two
samples, where the Liang Bua samples contain radiation hotspots surrounded by
non-active regions, whereas the Denisova Cave sediments have a more uniform
radioactivity distribution. The results of both profile sample measurements
demonstrate the variable extent of sample beta inhomogeneity and its relation to
the specific architecture of the sample under investigation (e.g., presence of
limestone clasts, bone fragments, etc.). The application of a mean dose rate for
samples such as that from Denisova Cave may accurately represent the average for
the bulk sediments, whereas for samples such as that from Liang Bua, which show
greater spatial variability in beta dose rate, a more individualized approach should
be considered.
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Figure 6.5 Spatially resolved dose rates in Denisova sample profile. Each sub-sample
is 10x10x6 mm3 in size.
Figure 6.6 illustrates sample dose rate inhomogeneity at the 0.44 x 0.44 mm2 (8x8
pixels) spatial resolution in the form of a frequency plot, with Denisova Cave dose
rates in red and Liang Bua dose rates in blue. The variability within each of the 50 x
10 x 3 mm3 profiles is shown, with dose rates ranging from 0.1 to 4 Gy/ka and 0.1 to
5.4 Gy/ka for the Liang Bua and Denisova Cave samples, respectively. The frequency
of dose rates above 4.8 Gy/ka in the Denisova Cave sample is so low that they are
not visible on the plot. While the Denisova Cave sample dose rate distribution
appears moderately Gaussian in shape, distributed around a value of 2 Gy/ka, the
Liang Bua dose rate distribution is positively skewed towards dose rates of < 1
Gy/ka.
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Figure 6.6 Frequency plot of the dose rate distribution within the Denisova Cave
(DA) and Liang Bua (LB) samples (including 5 sub-samples, front and back).
The errors in the derived dose rates depend on the spatial resolution (i.e., the
binning of the resulting single pixel data). Spatial resolution of 0.44 x 0.44 mm2 (8x8
pixels, figures 6.4 and 6.5) results in a relative error of 27.7% for the mean dose rate
of 0.71 Gy/ka in the Liang Bua sample, for a measurement time of 10 days. The
relative error decreases to 14.1% and 7.5% for spatial resolutions of 0.77 (16x16
pixels) and 3.10 mm2 (32x32 pixels), respectively. Radiation hotspots in the Liang
Bua sample, shown in red on the dose rate heat maps in figure 6.4 and
corresponding to dose rates of 2 Gy/ka and higher, have maximum relative errors of
16.7% and 5.0% for resolutions of 0.19 and 3.10 mm2, respectively. In the Denisova
Cave profile, the relative errors for the mean dose rate of 1.65 Gy/ka range from
18.3% to 5.3% for spatial resolutions of 0.19 to 3.10 mm2, respectively. The
radiation hotpots in the sample, capped at 3 Gy/ka in figure 6.5, have maximum
relative errors of 13.7% and 4.4% for spatial resolutions of 0.19 (8x8 pixels) to 3.10
mm2, respectively.
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Discussion

All three calibration curves are based on the beta particle rate, which is the most
relevant for dating due to its greater range in sediment and the removal by acid
etching of the alpha dose rate component when dating sand-sized mineral grains.
Since the Timepix detector is only able to provide the detection rate of the particle
type, radionuclide identification is not possible at this stage. The elemental
composition of the sample must be known or assumed to determine the sample
environmental dose rate. In principle, it is possible to use the Timepix for isotope
identification based on the detected particle energy, when the detector is used in the
“time-over-threshold” mode, which is energy calibrated. This method can be
investigated by distinguishing uranium and thorium radionuclides from potassium
by means of their alpha particles, and then use respective alpha particle energies to
identify the radionuclide. Other methods to determine elemental composition of the
sample, such as laser-ablation ICP-MS or electron microprobe analysis in a scanning
electron microscope, can also be applied.
The Denisova Cave and Liang Bua samples are known to have 40K as the principal
contributor to sample beta dose rate. When absorbed doses are quantified for single
grains, it is important to consider the distribution of sources around the dosimeter
grains, since it may have a significant effect on the sample age in some cases. In the
case of the LB,b (figure 6.4), the mean dose rate of the 3 x 102 mm3 sample would
yield a ~40% difference in age to that determined using the mean dose rate of the
entire 3 x 103 mm3 Liang Bua sample profile. The apparent difference in age between
a grain located at the bottom of LB,b, where there is a high concentration of 40K, as
compared to that of the top of the sample, where the dose rate is extremely low, is
~20%, both occurring within the 3 x 102 mm3 volume of this sample.
The same analysis of the Denisova Cave sub-sample shown in panel ‘e’ (figure 6.5),
in which the mean dose rate is higher than the average for the entire profile, results
in a decrease of age by 70%, as compared to the age determined using the average
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dose rate of 1.65 Gy/ka for the entire 3 x 103 mm3 profile. The calculated age of
grains located in the top left corner of this sub-sample, where 40K is less
concentrated, differs by ~40% from that estimated from the dose rates in the lower
part of the sample.
These potential age differences highlight the need to make multiple single grain De
measurements for age determination and to determine the beta dose rate from
sediments collected at an appropriate spatial scale (i.e., at the same scale as the De
values used for age determination).

6.5
40K

Conclusion

dose rates have been quantified for the Liang Bua and Denisova Cave samples,

the error margin is 7.5% or less (at 1σ) at spatial resolutions of 3 mm2, and 27.7%
or less for spatial resolutions of 1 mm2. Method weaknesses include the need for
measurement times up to 10 days, as well as a sample size that does not exceed the
area of the Timepix sensitive chip (14 x 14 mm2).
A procedure for measuring and deriving dose rates for intact sediment samples
using the Timepix pixelated detector has been developed and applied to samples
collected from two key archeological and hominin sights. A calibration curve has
been derived for 40K and the uranium and thorium decay series, and spatially
resolved Timepix beta particle count rates (measured in counts/pixel/second) can
be converted into environmental dose rates at the desired spatial resolution using
the determined count rate-to-dose rate relationships.
The proposed method is a novel application of the Timepix pixelated solid-state
semiconductor detector. In doing so, this study represents a further step towards
“grain-by-grain” dating of archeological and geological deposits, and a means of
improving both the accuracy and the precision of luminescence age estimates.

Chapter 7
Part 2
Real-time dosimetry: rationale and dose
calculation
Today cancer is the leading constituent of the disease burden in Australia: 1 in 4
women are diagnosed with cancer before the age of 75. Most commonly these are
breast, colorectal, lung, and gynecological malignancies, the latter generally
occurring in the endometrial lining and the cervix. In 2017 an estimated 2511
women had endometrial (i.e., uterine cancer), with a total of 494 deaths attributed
to the disease. For cervical cancer the incidence and mortality were estimated at
813 and 223 persons, respectively [77].

7.1

Rationale

Radiotherapy (RT) is prescribed to approximately 50% of all cancer patients, and
can be in the form of external beam or internal irradiation. Brachytherapy (BT) is an
internal radiotherapy treatment that allows irradiation directly within, or in close
proximity to the tumor target, and is a common treatment modality for patients
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with gynecological malignancies. BT can achieve higher biological doses as
compared to other RT modalities, but is limited to the sites that can be accessed
internally. It is the most conformal form of RT, offering reductions in both side
effects and post treatment toxicity, and thus can be used to treat patients who
cannot handle more aggressive treatments. Prostate BT, for instance, has shown
better prognostic features, as compared to EBRT and surgery [78]. EBRT patients
show worse bowel, sexual, and hormonal scores, while radical prostatectomy
patients show worse sexual summaries and urinary incontinence scores [79]. While
BT treatment setup is more complex and time-consuming, its benefits often
outweigh these shortcomings.
High dose rate brachytherapy (HDR BT) involves temporary implants and utilizes
sources with energies exceeding 50 keV and dose rates of ≥20 cGy/min, namely 60Co
and 192Ir. The dose gradient around HDR sources is ~10% per mm [80], and thus
extreme care should be taken to ensure proper targeting. Over time HDR BT has
become complex and hyperfractionation more frequent, increasing the risk of
potential mistargeting, and elevating the role of treatment quality assurance.

7.2

Iridium-192 and remote afterloader

Iridium-192 is the nuclide of preference for temporary implants in HDR BT. The
192Ir

active core is encapsulated in stainless steel, giving the source rigidity and

absorbing alpha and beta particles that are not used for treatment. The contribution
of bremsstrahlung is also considered negligible. 192Ir is a gamma emitter that decays
via beta minus decay (95.1%) and electron capture (4.9%). The 192Ir decay chain is
shown in figure 7.1 (based on ICRP Publication 38, 1983). For every beta minus and
electron capture decay ~ 2.2 photons with an average energy of 361 keV, and 0.1
photons with an average energy of 252 keV, respectively, are emitted [81]. Since the
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half-life of 192Ir is 73.81 days, the source must be changed at an interval of three to
four months.

Figure 7.1 Decay chain of 192Ir.
The HDR source is delivered using a remote afterloading device, that contains a
tungsten safe for source storage. The afterloader has two motor and control
systems: one for the HDR source, and one for the check source. The check source is a
non-radioactive cylinder, analogous in shape and size to the HDR source, and is used
to ensure transfer tube and catheter functionality prior to the release of the source
into the patient. The Flexitron afterloading device is shown in figure 7.2 without the
lid (7.2a), showing the tungsten safe and the drum containing the check source, and
with the lid (7.2b).
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Figure 7.2 Flexitron afterloading device with the lid (a) and without (b). Yellow
arrow in (b) points to the transfer cables that are connected to channels on the
drum, and then to the BT applicator channels inside the patient, and used as the
pathway for the HDR source.
Both of the sources are attached to steel wires that are wrapped around two drums
inside the afterloader. Stepping motors rotate each drum to allow the source to
enter its designated cable that corresponds to specific channels inside the
applicator. The microprocessor receives information on the required channels using
an encoder, and positions the source by monitoring the movement of the stepper
motor.

7.3

BT dose calculation

Dose calculation algorithms used in BT treatment planning are based on the TG-43
[82] and the updated TG43-U1 formalism [83]. They are based on a combination of
TLD measurements in water and MC simulations, and account for the 192Ir source
design. The dose to point P (figure 7.3) is calculated to account for its surrounding
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geometry, and the dose to water is quantified using a number of parameters
described below.

Figure 7.3 Reproduced geometry of the AAPM TG-43 dose calculation to point P [83].
In the line source approximation the dose rate in a water medium at point P, located
at radial distance r and polar angle θ from the source, is calculated as follows:

! !, ! = !! ∗ ! ∗

!! !, !
∗ !! ! ∗ ! !, !
!! !! , !!

(7.1)

!! is the air-kerma strength (unit of measurement: 1 U = 1 cGy.cm2.h-1) that is
numerically equal to the reference air-kerma rate (unit of measurement: 1 cGy.h-1).
Reference air-kerma rate (!!"# ) is the in-air kerma rate to air at the 1 m reference
distance !! . The two quantities are related by the following formula:
!! = !!"# ∙ !!!

(7.2)

!! (!) is the air-kerma rate in vacuum for photons above an energy of δ (in HDR BT,
δ=10 keV), and thus accounts for attenuation and scattering in any mediums
between the source and detector, as well as scattering from the floor, walls, and
ceilings of the facility. Distance ! is on the transverse plane of the source, from the
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center of the source to the point of the specified !! ! , and is large enough that any
variation in SK from source geometry is eliminated. Usually it is specified at a
distance of 1 meter:
!! = !! (!)! !

(7.3)

Λ is the dose rate constant in water, determined as the ratio of the dose rate at the
reference position and the air-kerma strength:
!=

!(!! , !! )
!!

(7.4)

!! is the geometry function, where θ is the angle of P with respect to the source
center, β is the angle subtended by both ends of the source (in radians), L is the
active length of the source, and r is the distance from P to the source center. For the
192Ir

line source:
!! !, ! =

!
! ∗ ! ∗ !!"#

(7.5)

(if θ≠0) and
!

!! !, ! = (! ! − ! 4)!!

(7.6)

if θ=0.
! ! is the radial dose function, which equals to 1 at r0 = 1 cm, and is used to adjust
for any reduction in dose from attenuation and scattering on the transverse plane,
that is not already accounted for by the geometry function:
!! ! =

! !, !! ∗ !! (!! , !! )
! !! , !! ∗ !! (!, !!

(7.7)

! !, ! is the anisotropy function that accounts for any dose variation with respect
to the polar angle, considering the scattering and absorption of photons resulting
from the source encapsulation, and potentially also the cable to which the source is
attached (it is equal to 1 on the transverse plane):
! !, ! =

! !, ! ∗ !! !, !!
! !, !! ∗ !! !, !

(7.8)

Real-time dosimetry: rationale and dose calculation

7.4

65

Gynecological HDR BT treatments

HDR BT is prescribed to patients with cervical, endometrial, and vaginal cancers,
often in combination with EBRT, chemotherapy, and/or surgery, according to
disease progression. It can be used as a monotherapy in low-risk cases, and as a
boost following hysterectomy to eliminate any residual disease from endometrial
cancer. The source can be administered to the cervix and vaginal cuff using
interstitial needles and intracavitary applicators. Interstitial treatments allow
superior targeting when the gross tumor volume (GTV) is clearly visible, whereas
standard applicators are more suitable in cases where a more uniform dose
distribution (e.g., for simpler tumor geometry) is required. The applicator is selected
based on target volume geometry, positioning of the organs-at-risk (OARs), and
pathological conditions [80]. Treatment targets including the uterus, cervix and
vaginal wall are densely vascularized and exhibit high radiation tolerance, but exist
in close proximity to radiosensitive OARs, namely the bladder, rectum, and sigmoid.
Patient geometry is shown on an MR image in figure 7.4 with OAR contours of the
bladder in blue, sigmoid in turquoise, and rectum in pink, as well as the high-risk
clinical target volume (HR-CTV) and GTV contoured in red and green, respectively.

Figure 7.4 MR image of patient geometry with HR-CTV (red), GTV (green), and OAR
contours (bladder in blue, sigmoid in turquoise, rectum in pink).
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The patient undergoes a clinical evaluation following diagnosis, and the treatment
goal is defined (i.e., whether it is local tumor control, palliative or curative
treatment). Treatments normally consist of 3-7 fractions, and an approximate
outline of the treatment flow is presented below (Erickson, Demanes et al. 2011.):
1. Applicator implantation.
Applicator implantation is carried out by the radiation oncologist, with the aid of
nurses and radiotherapy technicians, with or without anesthesia.
2. Image acquisition (normally with CT or MR) for visualization of the
applicator with respect to patient geometry.
The most common imaging modalities employed in the planning stage of the
treatment are computed tomography (CT) and magnetic resonance (MR) [84].
The cylindrical multichannel applicator and surrounding tissues are shown both
on CT (a,b) and MR (c,d) images of a gynecological patient plan in figure 7.5. The
arrows in the axial images (7.5a,c) demonstrate superior soft tissue visualization
provided by the MR image (7.5c), while the arrows on the sagittal images
(7.5b,d) demonstrate the superior applicator visualization on the CT (7.5b).
While MR minimizes artifacts arising from high-Z materials (that may be present
in the gynecological applicator) and offers high-resolution tissue visibility, CT
supersedes in its ability to visualize the applicator, and improves the accuracy of
applicator reconstruction [85].
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Figure 7.5 CT (top) and MR (bottom) images of the cylindrical applicator and
surrounding tissues for a gynecological patient.
3. Treatment planning using designated Treatment Planning Software and
CT/MR images to reconstruct the applicator, contour target volumes
and OARs, and optimize dose distributions.
The target is defined based on the location and type of disease, treatment course
(i.e., number of fractions and concomitant EBRT/chemotherapy/surgery), and
the goal of the treatment. The GTV encompasses the visible tumor, and the CTV
includes the GTV and an additional safety margin [86]. For treatments of the
vaginal cuff, the dose is most often prescribed to a volume located at a distance
of 5 mm from the surface of the applicator, with the vaginal wall as the treatment
target. OAR and target dose distributions are verified on the Dose Volume
Histogram (DVH). An example of a patient treatment plan prescribing 500 cGy
for a total of 5 fractions is shown in figure 7.6. Isodose lines correspond to 150,
100, 90 and 50% of the prescribed dose in the turquoise, red, yellow, and green
regions, respectively. Dwell positions in the central channel and one peripheral
channel are denoted by the red spheres, and OARs visible on the image include
the rectum (pink) and the bladder (blue).

Real-time dosimetry: rationale and dose calculation

68

Figure 7.6 CT treatment plan with isodose contours (150% of the prescribed dose is
shown in turquoise, 100% in red, 90% in yellow, and 50% in green) around the
cylindrical applicator. Dwell positions are shown by the red spheres.
4. Treatment dose delivery.
Transfer tubes are connected to the afterloader and their respective channels in
the applicator. Throughout dose delivery hospital staff monitor the patient
outside the BT bunker via an in-suite camera. Treatments usually last 5-15
minutes in length.
7.4.1 Quality assurance in HDR BT
A comprehensive quality assurance (QA) program provides verification against
possible treatment discrepancies (as a result of equipment and human error) at all
stages of the treatment, and thus ensuring the safety of patients, staff, and any other
affected persons. Each treatment consists of multiple steps and involves various
staff members along the way (summarized above).
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The arrival of new equipment at a clinical facility begins with acceptance testing of
the TPS, afterloader, source, and applicator. Acceptance testing for the HDR source
includes the verification of source identity, air-kerma strength, physical dimensions
and properties; for the applicator it includes the verification of the ability to deliver
the source to the intended positions and the evaluation of the applicator shielding
effect; for the TPS it includes the validation of system functionality using manual
calculations, checks for constancy, and testing using standardized plans.
Subsequently, a series of quarterly and daily checks take place, such as system
prompts for date/time and sound verification; shielding and exposure monitoring;
and specific procedures for source localization and temporal accuracy (usually
carried out upon source replacement).
The remote afterloader system has built-in quality assurance checks that ensure
applicator and source functionality in the pre-treatment stage. The afterloader
verifies catheter length and confirms that no blockages are present in the catheters
and transfer tubes using the nonradioactive dummy source. In the event of a
blockage the source is automatically retracted. An emergency stop motor inside the
afterloader is also able to retract the source upon the detection of unacceptable
source stepping discrepancies, or in the case that the source fails to return to the
tungsten safe. A reference point determined by the optopair inside the afterloader is
used to detect when the source passes between the safe and the channel selection
tube. Step size is verified by the microprocessor, with an error margin for variations
due to friction. The afterloader contains a primary and secondary timer for dwell
time verification. The primary timer calculates the total dwell time of all selected
positions, while the secondary timer verifies that this total dwell time is within ±1%
of the of the sum of the dwell times per channel and twice the time that the source is
in transit [87].
A check ruler is installed with Flexitron afterloaders in particular, and used to verify
source position and dwell time within ±2 mm and ±2%, respectively, accounting for
the transit dose. A QA check is carried out using the in-suite camera and stopwatch.
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During this check source position and dwell time are crosschecked to be within 1
mm and 1%, respectively of that indicated by the Treatment Console. Transit dose
and the possible rounding error that may arise during the transfer of the plan from
the TPS to the afterloader, are included in the error margin.
7.4.2 Errors in BT
A number of RT accidents occurred in the past despite the exhaustive pre-treatment
QA process [88-91]. Errors may occur during and before dose delivery — for
example in the planning phase with multiple specialists failing to detect a systematic
error [92]. Errors reported for HDR BT include the delivery of the wrong patient
plan, afterloader malfunction, indication of incorrect activity units, and source
staying inside the patient following treatment completion [93]. The consequences
can be as grave as death, and extend outside the treatment facility (e.g., radiation
exposure of bystanders). The frequency of BT errors is not thoroughly covered in
literature; the occurrence of transfer tube misconnections and patient organ and
applicator motion are often not known altogether. Errors are rare, but nevertheless
unavoidable, and may be consequential due to the high doses delivered per fraction.
Both over- and under- dosing the treatment area is undesirable, since lower doses
will result in an insufficient coverage of the tumor, whereas higher doses may cause
toxicity in the form of acute and late effects of radiation.
Treatment errors may be the result of mechanical events, such as malfunctions of
equipment, and human error, in one or more of the treatment phases. Potential
errors in manual procedures could take place during data entry (e.g., source
strength, step size, dose prescription, isodose value, and transfer tube, applicator
and indexer lengths); applicator insertion and reconstruction during treatment
planning and target contouring, especially in cases when the GTV is not clearly
visible; misconnection of transfer tubes between the afterloader and the applicator;
and general procedures (e.g., medical indication, patient identification, site of
treatment, prescription, and diagnosis) [94]. Additionally, post-imaging changes in
patient anatomy and applicator shifts may affect the dose distribution.
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Two potential errors that may take place in BT treatments are positional shifts of
the applicator and the interchange of transfer tube connections. Both of these errors
can alter the delivered dose distribution within the treatment region. An example of
a ~4 mm multichannel applicator shift in the para-sagittal plane is shown in figure
7.7, with the correct applicator positioning shown on the top images (7.7a,b) and
the implications of a modification in the applicator position shown on the bottom
images (7.7c,d). The yellow arrows in the figure point to the isodose contours in the
correct and shifted applicator positions. As a result of implant modification, the dose
distribution to the target also shifts in the same plane, and the target is no longer
encompassed by the intended 350-cGy dose in the para-sagittal plane (7.7b,d), and
the 400-cGy dose in the para-transveral (7.7a,c) plane. The applicator shift also
increases the dose to the rectal wall.

Figure 7.7 Para-transversal (a,c) and para-sagittal (b,d) views demonstrating the
effect of a ~4 mm shift in the cylindrical applicator position inside the patient. The
yellow arrows point to the isodose contours in the correct and shifted applicator
positions.
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The possible implications of a transfer tube misconnection, resulting in dose
delivery to the wrong channel inside the applicator, are shown in figure 7.8. The
arrows on the patient CT point to the two regions that will be affected by the
switched transfer tube connections. In this example, if the source dwells in channel
7 (7.8b) instead of the planned channel 3 (7.8a), the 2-cc volume of the rectum will
receive 6% more dose, whereas the target will be under-dosed.

Figure 7.8 Possible implications of a transfer tube misconnection shown on a patient
plan: instead of channel 3, channel 7 is connected on (b).
Both of the described errors (figures 7.7 and 7.8) can occur easily, and can affect the
outcome of the patient treatment. Moreover, unless the HDR BT treatment setup or
dose delivery is verified in real-time or post-treatment, these errors remain
unnoticed.
Moreover, most frequently errors do not occur due to equipment malfunctions, but
rather, due to human error, arising from mistakes, inadequate knowledge, and
miscommunication [13-16, 19]. The American Association of Physicists in Medicine
(AAPM) recommends QA of the entire HDR BT treatment process, outlined in detail
in AAPM TG-56 [95] and TG-59 reports [96]. The various QA procedures discussed
in section 7.4.1 thoroughly cover the treatment process prior to the dose delivery
phase. However no real-time or post-treatment quality assurance protocol exists to
verify that the dose delivery was carried out as intended by the radiation oncologist.

Real-time dosimetry: rationale and dose calculation

7.5

73

Real-time treatment verification

Real-time treatment verification that is able to fill in the gaps of pre-treatment QA
checks would increase the quality of cancer care for the patient. Such verification
has the potential to ensure that the treatment has been delivered according to the
treatment plan: the dose has been administered correctly to the tumor target, and
that intended minimal exposure of the surrounding tissues has been ensured.
Moreover, it contributes to the awareness of treatment errors, currently lacking in
the BT community, by monitoring the occurrence types and rates of frequency.
Some of the most essential characteristics of real-time verification systems include
the ability to identify HDR source position; accurately determine doses to the target
and organs at risk; provide precise knowledge of dosimeter location, all the
meanwhile allowing inherently low Type A statistical errors [97].
7.5.1 System requirements
Especially important concepts for dosimetry system evaluation are sensitivity and
specificity. Sensitivity describes the system’s ability to detect treatment errors, and
is expressed as the fraction of ‘true positives’. Specificity is expressed as the fraction
of ‘true negatives’ (i.e., system ability to identify the absence of error). However, an
increase in sensitivity results in a greater number of false positives, and thus lowers
specificity.
Other prominent considerations in dosimeter suitability for real-time BT treatment
verification include:
•

Energy dependence

•

Angular dependence

•

Dose rate dependence

•

Detector size (i.e., ability to incorporate the dosimeter into the existing
treatment accessories)
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Practicality of the system: robustness, stability, simplicity, and ease of
incorporation into existing treatment routine

•

Online readout

7.5.2 Two approaches
Two approaches to real-time BT treatment verification exist: in vivo dosimetry (IVD)
and the verification of HDR source positions and dwell times. IVD is the
measurement of absorbed dose to the target or organs-at-risk. HDR source
verification is the tracking of source positions and dwell times in the dose delivery
phase, using imaging or radiation detectors. When applied in real-time, both of these
methods allow the clinician to interrupt the treatment in case of error detection, and
prevent potential under-dosing of the tumor target and over-dosing of the OARs.

Chapter 8

Real-time BT QA: In vivo dosimetry
The aim of in vivo dosimetry is to serve as an independent and accurate method of
verification of the dose to the target or organs-at-risk during the dose delivery
phase. It can be used as a tool to verify dose at specific points within the treatment
region, and thus detect errors causing an impact on the absorbed dose.

8.1

In vivo dosimetry for treatment verification

Major national international organizations such as the International Atomic Energy
Agency (IAEA), World Health Organization (WHO), International Commission on
Radiological Protection (ICRP), American Association of Physicists in Medicine
(AAPM) and European Society for Radiotherapy and Oncology (ESTRO) recommend
the use of IVD for treatment verification, however, it has not been widely integrated
into regular treatment flow, except in the case of external beam radiotherapy
(EBRT) total body irradiation. This is due to a number of reasons that arise both
from the logistical and technical aspects: cost ineffectiveness, complexity of use and
laboriousness of existing systems, shortage of resources and inefficiency, and the
absence of set decision criteria for dealing with detected discrepancies. Moreover,
the value of IVD is under question, with systems lacking in their capability to detect
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a sufficient number of relevant errors to justify efforts, and a wide belief that the
pre-treatment QA checks provide enough confidence in the treatment. Therefore
IVD methods must be further developed to achieve higher accuracy, practicality, and
user-friendliness.
In addition to BT treatment errors discussed in section 7.4.2, uncertainties in the
absorbed dose may occur as a consequence of TPS algorithm shortcomings, such as
failure to account for appropriate scatter conditions and tissue inhomogeneity. The
finite patient volume as opposed to the infinite medium used in dose calculation,
interfaces between different densities (i.e., tissue-to-air), and shielding by the
applicator [98] may change the dose to the target. Clinical dose distributions in the
planned target volume (PTV) may be affected by up to a factor of 10, either underor over-estimating the dose [99]. The presence of the applicator may also affect the
dose, especially for the organs in proximity to the PTV (e.g., the bladder and rectal
wall), and result in an overestimation of the reported OAR dose for toxicity
assessments due to a lower-density interface, such as the skin surface of the patient
in breast cancer treatments [100].
8.1.1 IVD systems
Passive dosimetry systems most prominently used for BT treatment verification are
TLDs [101-105] and film [106, 107]. TLDs come in various forms (e.g., rods, chips,
ribbons, powders) and are valued for their robustness and small size, long lifetime,
dose linearity, flat energy dependence, capability of measuring dose to tissue, and
dynamic range for both high and low energy sources [108]. TLDs show the least
sensitivity dependence on detector position, with response varying by 10-15% over
the 1-10 cm range with respect to 192Ir [109]. However, TLDs have to be annealed,
exhibit fading, and can be expensive. Film has been widespread due to its ease of
use, 2D dose distribution mapping, and energy independence; however it requires
multiple measurement corrections such as those addressing film darkening and
non-uniformity [110]. The major drawback of the aforementioned techniques is that
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detected errors cannot be addressed during the treatment, since they are
recognized following treatment completion.
A number of real-time IVD systems have been studied that allow the treatment to be
interrupted or terminated, in case of major dose discrepancies from the treatment
plan. These include electronic portal imaging devices (EPIDs) [111-113], plastic
scintillation detectors (PSDs) [114-117], optical fibers coupled to a small aluminum
oxide crystal [118], diodes [119-122], and metal oxide semiconductor field effect
transistors (MOSFETs) [123-126]. EPIDs are constructed according to amorphous
silicon photodiode technology, and show dose rate independence, can be calibrated
in terms of tissue dose; however they exhibit angular dependence, over-respond to
low energy photons and have a response lag [113]. PSDs are able to measure tissueequivalent dose as a function of the light emitted by the polymerized solvent that is
transmitted via an optical fiber to a photodetector. These systems have a small
sensitive volume, long lifetime, show dose linearity and energy independence, and
can be read out with nanosecond precision. Their shortcomings include high
background (i.e., stem signal and temperature dependence) when used in vivo [127,
128].
Diodes and MOSFETs are both semiconductor dosimeters. Diodes have a response
that is dependent upon energy, dose rate, temperature, and angle of incidence, and
are known to change in sensitivity with changing source-to-detector distance (SDD)
due to the variation in photon spectra. However their strengths often outweigh the
shortcomings due to characteristics such as high sensitivity, robustness, long
lifetime, ability of online readout, and simplicity of use [128]. The MOSFET is a type
of transistor used for amplifying or switching electronic signals, and MOSFET
dosimetry systems measure dose as a function of the change in threshold voltage.
They are small in size, capable of displaying dose to tissue upon readout, and do not
exhibit temperature dependence once equilibrium has been reached for a range of
temperatures between 15 and 40° C [129]. MOSFETs require angle, energy, and
sensitivity corrections with accumulated dose, and have a limited lifetime. Both
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diode and MOSFET systems can be used in real-time also in passive mode, giving
them an additional advantage of performing IVD without the application of a bias.
It is often difficult to select the ideal dosimeter for surface dose measurement due to
the dose build up and scattering resulting from treatment equipment and shielding.
MOSFETs have been compared to TLDs in anatomical sites such as breast, neck,
chest, back, and nose and were found to be in good agreement. MOSFETs showed
advantages over TLDs due to simple calibration, maintenance and operation, and
the possibility of immediate readout. TLDs proved to be more laborious due to
annealing, dependence on environmental conditions, and inherent impurities [130].
8.1.2 MOSFET dosimetry
MOSFETs have been used for EBRT dose measurements in anatomical sites such as
the nose [131], breast [132], chest [133] and pelvis by placing dosimeters on the
skin layer of the desired site [134], as well as under acrylic masks for head and neck
patients [130, 135]. IAEA Human Health Report No. 8 describes MOSFET use for
EBRT treatment monitoring, mainly to check the entrance dose in similar
anatomical sites as Ramani et al. (1997), including the pelvis, head and neck, breast,
and others [136]. MOSFETs have also been successfully applied to eye dosimetry in
pediatric cranial CT scans [137] and neuro-interventional procedures [138]. In
prostate treatments MOSFETs have been placed on rectal balloons during EBRT
[135]; on urinary catheters to monitor the dose to the urethra in low dose rate
(LDR) BT implants [124, 139], and on ultrasound probes for rectal wall dosimetry in
HDR BT [140].
A feasibility study placing sterilized MOSFET dosimeters (coupled to a positionsensor) in a urinary catheter has also been performed for gynecological HDR BT,
and determined positional accuracies of 1 mm within a 1-10 cm SDD, concluding the
potential to detect a 2-mm movement of the bladder [141]. The above studies have
demonstrated the capability of MOSFET dosimetry systems in successful real-time
in vivo treatment verification.

Real-time BT QA: In vivo dosimetry

8.2

79

Aim of this chapter

This chapter addresses the IVD approach to gynecological HDR BT treatment
verification using MOSFET-type MOSkin dosimeters. The primary aim was to
develop, test, and apply a rectal wall IVD system in an in-phantom feasibility study,
followed by the clinical application of the developed system to an in-patient study.
The secondary aim was to investigate a method of simplified MOSkin calibration
adjustment for IVD, and propose a post-IVD MOSkin quality control (QC) check
utilizing a low-activity beta source.
The feasibility study has been published as Romanyukha, A.A., Carrara, M., et al.,
Applications of MOSkin dosimeters for quality assurance in gynecological HDR
brachytherapy: An in-phantom feasibility study. Rad. Meas. (2016),
http://dx.doi.org/10.1016/j.radmeas.2016.12.010.
The in vivo application of the method has been published as Carrara, M.,
Romanyukha A.A., et al., Clinical application of MOSkin dosimeters to rectal wall in
vivo dosimetry in gynecological HDR brachytherapy. 41 Phys. Med. (2017): 5-12.
10.1016/j.ejmp.2017.05.003.
The MOSkin calibration adjustment study has been prepared for submission to
Physica Medica Journal as Romanyukha, A.A., Carrara M., et al., Defining a simplified
method of MOSkin calibration for in vivo dosimetry in a clinical setting.

8.3

MOSkin dosimeters

MOSkin dosimeters are MOSFET-type detectors originally developed for skin dose
measurements at the Centre for Medical Radiation Physics (CMRP) in the University
of Wollongong (UOW) to address some of the traditional MOSFET dosimeter
shortcomings [142]. The detectors are four-terminal devices consisting of the
source, gate, drain, and substrate (figure 8.1).
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Figure 8.1 Schematic structure of the p-type MOSFET dosimeter.
The gate oxide (i.e., MOSkin sensitive volume) is made of a 4.8 x 10-6 mm3 silicon
oxide placed on silicon substrate (350 µm thickness). It limits dose-averaging effects
arising from larger sensitive volumes, allowing optimal point measurements in high
dose gradients. The threshold voltage VTH is the voltage required for current to flow
between the source and the drain, and the shift in VTH (i.e., Δ VTH) is proportional to
the absorbed radiation in the gate of the MOSFET.
The silicon chip is assembled over a Kapton pigtail with the complete detector probe
measuring 350 x 3 x 0.4 mm3. In traditional MOSFET dosimeters the sensitive
volume is protected by a bubble epoxy resin layer lacking reproducible thickness,
making it unsuitable for skin dosimetry. However, MOSkin geometry contains a thin
0.07-mm water equivalent depth (WED) build-up layer of Kapton (shown in figure
8.2) that is achieved by special CMRP packaging technology of silicon sensors,
making it ideal for dose measurements at the surface level.
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Figure 8.2 Traditional MOSFET geometry (a) with epoxy bubble for sensitive volume
protection and MOSkin geometry (b) with a 0.07-mm Kapton build-up layer,
allowing surface level dose measurements.
MOSkin, as a p-channel MOSFET, requires a positive bias on the gate during
radiation exposure, causing charge separation: the electrons are pulled towards the
gate, and the holes toward the interface between Si and SiO2. Holes are captured
into traps at the interface to form a positive charge layer. Threshold voltage changes
a function of dose, as follows:
ΔVTH ~ 0.0022 ! D0.4 ! t2ox

(passive mode)

(8.1)

ΔVTH ~ 0.04 ! D ! t2ox ! f

(active mode)

(8.2)

where D: dose
tox: oxide thickness
f: fraction of holes escaping recombination
Dosimeter sensitivity is primarily determined by the oxide thickness and the
electrical field. A higher bias during irradiation causes a larger proportion of charge
collection, increasing the sensitivity of the device and reducing the total dose the
device is able to record before saturation. The gate threshold is known to vary with
temperature, and depends on the amount of radiation exposure the detector has
received. Other shortcomings include angular dependence, finite shelf life, and dose
fading.
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The MOSkin readout system is the Clinical Semiconductor Dosimetry System, a
dedicated microprocessor reader, which acquires and integrates the signal over the
selected interval from up to five dosimeters at a time (figure 8.3). The readout
interval can be set as low as 1 second. A bias of 0-15 V (established as thermostable
during current-voltage detector characterization) can be applied on dosimeter gate
during radiation exposure, and this way measurement sensitivity can be adjusted to
accommodate the specific application. Accompanying MosPlot readout software was
also developed at CMRP, allowing graphical and numerical representations of the
instantaneous and total ΔVTH shifts. Detector sensitivity factors obtained during
calibration can be defined prior to measurement to display absorbed dose (cGy) in
real-time.

Figure 8.3 Clinical Semiconductor Dosimetry reader with one MOSkin detector
connected.
Errors due to reader uncertainty for consecutive readings and the creep-up effect
(i.e., charge arising from the measuring circuit) were quantified as ±1 mV and ≤4
mV, respectively, and together contribute to < 1% error, given that the integral dose
is recorded following a 1-minute time interval. The fading effect (i.e., reduction of
charge following radiation exposure) of MOSkins is avoided if readout is recorded
within 15 minutes of irradiation. Since the acquired data is automatically stored in a
data file, the creep-up and fading effects, respectively, are accounted for by
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recording the ΔVTH once a plateau is reached (in the case of post-measurement data
analysis).
The detectors have been optimized to measure dose in steep dose gradients, as
those characteristic of HDR BT sources such as 192Ir [143], and fully characterized in
previous studies [144]. MOSkins were found to accurately determine doses in steep
dose gradients as well as at interfaces, correctly reproduce tissue scattering
conditions, and allowing to determine the dose to tissue at the time of readout.
8.3.1 MOSkin calibration
8.3.1.1

INT HDR BT facility

The following studies took place at the Istituto Nazionale dei Tumori (INT) in Milan,
Italy. The HDR BT facility was equipped with the microSelectron HDR remote
afterloading device and Oncentra Brachytherapy TPS for treatment planning, both
provided by Elekta (Nucletron Elekta, Veenendaal, Netherlands). The afterloading
device allows up to 30 transfer tube connections, a positional accuracy of ± 1 mm,
and a minimum step size of 2.5 mm. The lowest dwell time setting is 0.1 seconds.
The active length of the 192Ir source was 3.6 mm with an active diameter of 0.65 mm
[87]. The source reference air-kerma rate was certified to be within 5% (k=3) by the
vendor calibration certificate, and then verified at INT using a primary standards
dosimetry lab-traceable well type ionization chamber of 200cc vented sensitive
volume [145].
8.3.1.2

Calibration procedure

For calibration, each dosimeter is positioned in the center of a 100 x 100 x 100 mm3
LR Plastic Water phantom slab (CIRS, Norfolk, VA). The plastic needle delivering
192Ir

was placed at a distance of 21 ± 0.1 mm from the center of the MOSkin sensitive

volume, chosen in consideration of the predicted SDD for IVD in rectal wall dose
measurements. An additional 100 x 100 x 100 mm3 of scattering volume was added
below the source to ensure adequate scattering conditions [100]. The calibration
setup is shown in figure 8.4. Prior to each calibration, Oncentra was used to
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determine the dwell time corresponding to a dose of 100 cGy at the selected
distance using a CT scan of the calibration setup. The TPS-determined dwell time
was crosschecked using an AAPM TG-43-based Matlab script for dose calculation.

Figure 8.4 MOSkin calibration setup.
ΔVTH readings M were taken at an interval of 5 seconds by applying a 15-V bias on
the detector, ensuring response stability of the detector. The calibration coefficient
NS (cGy/mV) was determined as the quotient of the dose rate, calculated as the
delivered dose (cGy) per dwell time (s), and the slope of the ΔVTH shift per unit time
(mV/s). Once the dosimeters have been calibrated the absorbed dose D was
determined from M (measured in mV) as follows:
D = M·Ns

(8.3)

An example of calibration curves for three dosimeters is shown in figure 8.5. In this
case 100 cGy were delivered for a total source dwell time of 42.4 seconds. Linear fits
were derived, serving as the calibration coefficient, and correspond to 2.53, 2.36 and
2.48 mV/cGy for the three dosimeters, respectively, with R2-values of 0.999 in all
cases.
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Figure 8.5 Example of calibration curves for three MOSkins, with calibration
coefficients of 2.53,2.36 and 2.48 cGy/mV determined for the three dosimeters,
respectively.

8.4

Simplified method of MOSkin calibration adjustment

A change in MOSFET detector sensitivity is known to occur with radiation exposure.
In order to ensure precise dosimetry, calibration coefficients obtained prior to
radiation exposure must be adjusted throughout the lifespan of the detectors. The
calibration adjustment is usually determined by repeating the calibration
procedure, which can be time consuming and impractical due to the necessity of the
BT facility, that is often occupied for patient treatments in the clinic. A simplified
method of MOSkin sensitivity measurement, which can be carried out outside the BT
bunker without demanding strict radioprotection requirements, would thus
facilitate the calibration adjustment procedure.
8.4.1 MOSFET change in sensitivity
A number of studies have investigated this topic, and have come to a similar
conclusion: precise dosimetry demands either recalibration or a shortened MOSFET
lifetime [125, 135, 136, 140, 146-148]. The IAEA has recommended a recalibration
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of MOSFET dosimeters following a total dose of approximately 23 Gy (i.e., 2/3 of the
estimated detector lifetime) [136]. Ramani et al. (1997) avoided calibration
adjustments by discontinuing MOSFET use at dosimeter accumulated threshold
voltage of ≥18.5 V [130]. Haughey et al. (2011) found MOSFET dosimeters in a rectal
wall IVD study unsuitable, citing the change in the response of the detector as one of
the main reasons [125].
Fagerstrom et al. (2008) quantified the change in MOSFET (Dose Verification
System, Sicel Technologies) sensitivity using third order polynomials [146],
whereas Haughey et al. (2011) found a 1 ± 0.8% change per 0.5 V in the calibration
of the dosimeters when testing them for gynecological and prostate IVD. Zilio et al.
(2006) determined MOSFET reproducibility between 3.5 and 4.5% per V [148]. For
MOSkins in particular, Hardcastle et al. (2010) found measurements to be
reproducible within 1% for doses up to 10 Gy, after which the dosimeter was
discarded due to the nature of the rectal balloons used in the IVD study [135].
Recalibration has been recommended for MOSkins at every 5 V of accumulated dose
[147], which corresponds to a dose of ~22 Gy, or approximately four HDR BT
fractions. In the prostate IVD study carried out by Carrara et al. (2016) the
dosimeters were recalibrated after use in three HDR BT fractions, or following a
cumulative dose of 15 Gy [140].
It is evident that the adjustment of initial dosimeter calibration is mandatory, and
currently involves a replication of the initial calibration procedure described in
section 8.3.1.2, involving the BT theater or linear accelerator bunker, in addition to
the transport of the phantom to the relevant facility. Treatment rooms remain busy
throughout the day in the clinic, and cannot be accessed for calibration purposes.
Moreover, the phantom that ensures proper scattering conditions is heavy and
difficult to transport.
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8.4.2 Aim of this study
MOSFET dosimeters are known to be energy-dependent, and it has been noted
previously that the accumulated dose effect is not linear between sources of varying
energies, and thus cannot be adjusted for using a single correction factor [146]. The
aim of this study was to investigate a method utilizing the ratio of dosimeter
sensitivities to the RT and a low-activity source for MOSkin calibration adjustment,
throughout its use in the clinic. The low dose rate-emitting 90Sr source was used to
adjust MOSkin calibration coefficients for absorbed dose measurement in EBRT
beams of 6 and 15 MV, and the HDR BT 192Ir source. The goal was to simplify MOSkin
recalibration employing a source that does not require extensive radioprotection
precautions, such as the shielding necessary for BT and EBRT treatments, is
compact, and can be used inside an office or a laboratory.
Moreover, to provide confidence that the detector has functioned properly
throughout measurement and has yielded reliable results, a method for MOSkin
quality control following IVD is proposed utilizing the 90Sr source.
8.4.3 Materials and Methods
Six brand new MOSkin dosimeters were selected for the study: three for use with
192Ir,

and three for measurement with the linear accelerator (linac) beams. MOSkin

sensitivity ratios between 90Sr and RT sources were calculated at three stages of
detector lifetime, separated by 15 Gy of total accumulated dose. At each stage
MOSkin response to 90Sr was acquired first, followed by measurement with the RT
source. MOSkin response ratios between 90Sr and each RT source were determined
and evaluated as a function of total detector accumulated dose.
8.4.3.1

The 90Sr source

The 90Sr source was selected due to its accessibility in the RT clinical environment. It
is commonly used in the hospital as a check-source for Markus and Farmer
chambers to verify their stability and determine correction factors for air density
prior to use in EBRT QA practices [149]. The source (type T48012, PTW, Freiburg,
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Germany) has a half-life of 28.7 years, an activity of 33 MBq, and decays by β− decay
with beta energy of 0.546 MeV. Its decay scheme is shown in figure 8.6, and includes
a 2.28 MeV β− decay from yttrium-90 (T1/2 of 64.1 h) to the stable zirconium-90.

Figure 8.6 Decay scheme of 90Sr.
The manufacturer reports a dose rate below 1 µSv/h at a distance of 10 cm from a
closed-cover source [150]. The source is packaged inside a shielded container and is
accompanied by a plastic holding device measuring 10 cm in diameter and 2 cm in
depth. It consists of two precisely aligned top and bottom pieces, allowing the 90Sr
source to be fixed in place during measurement. Due to the long half-life of the
source any change in activity during this two-week study was considered negligible.
8.4.3.2

MOSkin sensitivity measurements

The most widely used EBRT beams of 6 and 15 MV, respectively, were selected.
Linac output was confirmed for each energy spectrum according to the IAEA TRS398 protocol utilizing the Farmer ion chamber (NE2581). MOSkins were positioned
on top of a 100 mm-thick LR Plastic Water phantom for backscatter, with maximum
buildup depths of 15 and 30 mm for beams of 6 and 15 MV, respectively. A dose of 1
Gy at a rate of 200 MU/minute was delivered at SSD of 100 cm, with ΔVTH read out at
a 5-second interval. Calibration coefficients N6MV and N15MV were calculated as
described in section 8.3.1.2.
To quantify 90Sr sensitivity, each MOSkin was placed directly below the open 90Sr
source inside the plastic holding device (figure 8.7a), centering the sensitive volume
on the lower piece so that it directly faces the active part of the source (figure 8.7b).
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Due to the thinness of the detector pigtail it was possible to align the two plastic
pieces precisely and without gaps.

Figure 8.7 90Sr plastic holding device, consisting of a bottom (a) piece where the
MOSkin was fixed, and a top piece (b) where the source was positioned. Irradiation
geometry is shown in (c) with the source active area positioned directly above the
MOSkin sensitive volume.
An integral dose of 15 Gy was delivered between sensitivity measurements (i.e.,
between stages 1 and 2, and stages 2 and 3, respectively), using the RT source, to
simulate three stages of detector lifetime. MOSkin response to each source was
acquired three times, delivering a total dose of 3 Gy at each stage. The dose
delivered by 90Sr could not be precisely quantified, but is estimated to be no more
than 3 Gy throughout the entire experiment (i.e., when applying the 6 and 15 MV
EBRT calibration coefficient). Total doses received by the dosimeters were 39 and
48 Gy in BT and EBRT experiments, respectively. A chronological schematic of the
experiment is shown in figure 8.8.
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Figure 8.8 Schematic plan of MOSkin measurements throughout the
experiment, where each section corresponds to the irradiation type, and each
subsection corresponds to one irradiation.
For measurement of MOSkin sensitivity to 90Sr, the detectors were positioned as
shown in figure 8.7, and M readings were taken at a 15 second-interval, for a total of
120 s by applying 15 V to the gate of the MOSkin in each readout step. The
relationship between the acquired ΔVTH and time was evaluated by determining the
slope of the linear fit of the measurement (mV/s). The mean linear fit of the three
irradiations was determined, and its inverse (i.e., NSr90, s/mV) was used to describe
MOSkin sensitivity to 90Sr.
MOSkin sensitivity to the RT sources was evaluated in terms of calibration
coefficients at each stage of accumulated dose. The procedure for BT 192Ir source
calibration is described in section 8.3.1.2, and calibration coefficients NIr192 were
obtained as the mean of the three 1-Gy irradiations.
8.4.3.3

Ratios of MOSkin sensitivity to 90Sr and RT sources

MOSkin response ratios Ks(t) between 90Sr and RT source S were determined at each
stage t for 192Ir, 6 MV and 15 MV individually, as follows:
!! !

K! ! = !

!"#$

!

(8.4)
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The least squared method was used to investigate the linear fit of the Ks(t) as a
function of VTH(t), and resulting linear correlations were evaluated by the Pearson
Product Moment correlation coefficient r.
8.4.4 Results and application of method
8.4.4.1

Results

Mean Ns values at each of the three stages of detector lifetime are reported in Table
8.1. The decrease in MOSkin sensitivity with accumulated dose was determined as
3.0 ± 0.9 % per 10 Gy, with minimum and maximum values of 2.1% and 4.6%
respectively. Variability in the response of the three dosimeters also increased with
accumulated dose, represented by the increase from a mean variability of 5.1% at
stage 1 to 6.3% at stage 3, further supporting the individuality of the sensitivity
changes in each dosimeter.
STAGE

Average Ns

σ (%)

Ir

0.378 cGy/mV

3.5

6 MV

0.402 cGy/mV

4.2

15 MV

0.414 cGy/mV

4.2

1.948 s/mV

8.4

Ir

0.405 cGy/mV

3.8

6 MV

0.428 cGy/mV

4.4

15 MV

0.443 cGy/mV

5.2

2.043 s/mV

8.4

Ir

0.441 cGy/mV

2.8

6 MV

0.461 cGy/mV

6.8

15 MV

0.475 cGy/mV

7.7

2.152 s/mV

7.7

SOURCE
192

1

90

Sr

192

2

90

Sr

192

3

90

Sr

Table 8.1 Mean Ns values at each of the three stages of detector lifetime, and
corresponding σ values indicating the reproducibility of MOSkin response.
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Ks(t) ratios were plotted as a function of detector VTH, recorded prior to each
irradiation. Each data point corresponding to the stage of dosimeter accumulated
voltage was obtained as the mean of the three irradiations and the three dosimeters
for each irradiation type. A linear relationship between VTH and Ks(t) ratios was
established as follows:
Ks = mS ·VTH + bs

(8.5)

mS indicates linear slope, determined as 0.0009 and 0.0012 cGy/s/V for the BT and
linac beams, respectively. The introduction of bs values offers a dosimeter-specific
sensitivity adjustment, supported by the increased variability between the response
of individual detectors with accumulated dose, reported in table 8.1. Individual
curves are plotted in figure 8.9, with bs values of 0.1975, 0.1771, 0.1829 cGy/s for
the BT source and EBRT beams of 6 and 15 MV beams, respectively. The
corresponding R2 values for the three curves were 0.976, 0.992, and 1.0, resulting in
p-values of 0.099, 0.057, and < 0.00001 on the 0.1 confidence level.

Figure 8.9 Mean Ks(t) values (i.e., averaged over the three irradiations and three
dosimeters), plotted as a function of detector VTH, with error bars corresponding to
the variability between the three dosimeters.
8.4.4.2

KS application for MOSkin calibration correction

Initial calibration is performed with the RT source according to the conventional
procedure, and dosimeter response to 90Sr is obtained. At the initial t0 stage of
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MOSkin calibration, KS(t0) are determined for each dosimeter, using the acquired
NS(t0) and NSr90(t0) (according to equation 8.4). bs values stay constant throughout
the life of the dosimeter, and are calculated as follows:
bs = KS(t0) · mS · VTH(t0)

(8.6)

Combining equations 8.4 and 8.6, results in:
Ns(t) = NSr90(t) · [mS · VTH(t) + bs]

(8.7)

Finally, from the combination of equations 8.6 and 8.7, the calibration coefficient
can be adjusted to account for the decrease in MOSkin sensitivity, at any time t,
using its VTH(t) reading and post-IVD response to 90Sr, as follows:
NS(t) = NSr90(t) · [KS(t0) + mS · (VTH(t) - VTH(t0))]

(8.8)

The standard error of this approach was calculated as 0.1±1.4% at all three stages of
accumulated voltage. Total Type A uncertainties were quantified as 1.51%,
including MOSkin measurement reproducibility for both the RT and 90Sr sources,
determined as 0.95 and 1.17%, respectively.
8.4.5 Discussion
Electronic equilibrium within the detector volume is assumed due to the small
sensitive volume of the MOSkin, the use of large 10x10 cm2 field sizes in EBRT
irradiations, and adequate scatter and build up conditions, as recommended by
AAPM and ESTRO for HDR BT [100] and by the IAEA TRS-398 protocol for EBRT
applications.
As the MOSkin is exposed to increased amounts of radiation, there is a decrease of
the electric field in the SiO2 layer of the MOSkin sensitive volume due to holes
trapped on the Si-SiO2 interface, which would lead to a stronger recombination of
electron-hole pairs produced by ionizing radiation in the gate of the MOSFET and in
particular particles of higher LET, such as the electrons of 90Sr (i.e., the average
photon energy of 192Ir is 0.361 MeV, as compared to the spectra of the 6 and 15 MV
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linac photons, and the 0.546 MeV electrons measured from 90Sr). This study
presents a characterization of this effect by proposing an adjustment that takes into
account the amount of dose accumulated on the detector in the calibration
coefficient adjustment. The dose accumulated on each dosimeter as a result of the
90Sr

irradiations showed an average ΔVTH of 0.68 V, influencing the total decrease in

dosimeter sensitivity by <1%, and thus considered negligible.
It is also possible to correct for change in MOSkin sensitivity by assuming a uniform
accumulated dose effect between dosimeters. For the dosimeters irradiated in this
study, sensitivity was found to change by -3.0% per 10 Gy on average, and would
have resulted in an average calibration coefficient error of 2.4±4.7%, that increases
with accumulated dose to 4.7 ± 5.9% at stage 3 of detector lifetime. These errors are
0.9 and 3.2% higher, respectively, than the error attributed to the approach
described in this study.
8.4.6 Post-treatment QC check
Measurement precision can be ensured against any significant change in sensitivity
to radiation or overall damage of the device by means of a simple post-treatment
quality control check [151]. A method for MOSkin QC following IVD is proposed
using the 90Sr source and employing the above uniform accumulated dose effect
assumption over all MOSkins.
Ks values obtained as a function of the post-treatment detector response to 90Sr (i.e.,
Ks,est), can be cross-checked against the expected Ks (i.e., Ks,exp,), assuming normal
detector functionality at the current state of accumulated voltage. The estimated
Ks,est can be derived according to equation 8.4, as the quotient of the Ns(t0), and
NSr90(t), measured following the treatment. The initial calibration factor can be
adjusted using the expected average MOSkin detriment (quantified as 2.96% per 10
Gy in this study).
The Ks,exp can be calculated as a function of VTH(t), following equation 8.5, where the
bs is derived for the applicable radiotherapy source at t0. If the values of Ks,est and
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Ks,exp agree within ±3.12% (i.e., three standard deviations) of MOSkin measurement
reproducibility, it can be assumed that the detector has functioned properly
throughout the treatment.
8.4.7 Conclusions
This proposed method utilizing the 90Sr check source simplifies the sensitivity
adjustment procedure, no longer requiring the radiotherapy facility and the large
phantom, following the initial calibration of the source. The use of 90Sr does not
demand any stringent radioprotection measures, and provides a reliable relative
measurement of MOSkin response in the case of linear accelerator beams and the
192Ir

brachytherapy source. Moreover, the proposed method can be employed as a

QC check of the dosimeter to ensure accuracy of the performed IVD. In principle, it is
also possible to extend this approach to other MOSFET dosimeters.
This work serves as a proof of method, and further measurements would be
required to support these preliminary results prior to the implementation of such
technique in a clinical setting.

8.5

In vivo verification of the rectal wall dose in gynecological
HDR BT

The upper part of the rectal wall, a major OAR in gynecological HDR BT treatments,
that is known to be more radiosensitive than the rest of the rectum [80, 114], was
chosen for dose verification. An IVD method employing MOSkin dosimeters was first
developed and a feasibility study of the proposed setup was performed. Following
positive results of the feasibility study, the method was extended to in-patient
application.
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8.5.1 IVD system description
A common semi-flexible rectal probe was assembled with three MOSkin dosimeters
positioned 10 mm apart, to constitute the dosimetric rectal probe (DRP), allowing a
simultaneous point-dose verification in three positions along the rectal wall (figure
8.10).

Figure 8.10 Schematic representation of the DRP (not drawn to scale), constituting
of a common semi-flexible rectal probe was assembled with three MOSkin
dosimeters positioned 10 mm apart, and pigtails wrapped around the surface of the
probe. A lead radiopaque marker is placed close to the top of the probe to aid in
dosimeter localization on the CT images.
MOSkins were calibrated as described in section 8.3.2 prior to probe assembly. The
probe was filled with gel in order to eliminate any air cavities and ensure proper
scattering conditions. A lead radiopaque sphere was attached at a known fixed
position at the top of the catheter to aid with MOSkin localization on the acquired CT
images. MOSkin position was determined on the sagittal view of the CT in Oncentra
TPS by defining the central axis on the surface of the probe, in the center of the
marker. Each resulting position was then crosschecked with dosimeter positions,
measured using a ruler following DRP assembly. A rotation marker indicating
upward probe rotation was placed at the bottom of the DRP to aid the radiation
oncologist in ensuring that MOSkins are facing the top of the rectal wall.
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8.5.2 Feasibility study
The aim of this study was to test the proposed IVD procedure in-phantom,
simulating the conditions of the actual treatment, and evaluate the resulting dose
discrepancies between measured and planned doses to determine the feasibility of
the proposed method for in-patient use.
8.5.2.1

Materials and methods

Dose evaluations were performed in two applicator types used for vaginal
treatments at INT: the single-channel and multichannel vaginal cylindrical (MVC)
applicators. A wooden plaque was positioned between the applicator and DRP to
simulate the anatomical distance between the rectal wall and the vagina. The plaque
also aided in the stabilization of the setup throughout the experiments (figure 8.11).

Figure 8.11 DRP and multichannel applicator setup, separated by a wooden plaque
to simulate the distance between the vaginal and rectal walls.
The setup was then inserted in the center of a 1 m3 water phantom, ensuring
sufficient backscatter conditions. The experimental setup is shown on figure 8.12,
where the DRP and applicator setup (figure 8.11) are visible inside the water
phantom. The three MOSkin detectors are connected to the reader, which in turn is
connected to a laptop with the MosPlot readout software.
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Figure 8.12 Feasibility study experimental setup: (a) entire setup including the
water phantom, reader, and computer with readout software and (b) zoomed in
schematic of the DRP and applicator setup inside the water phantom (schematic not
to scale), with the HDR source delivered through the applicator channels connected
to the afterloader by transfer tubes.
CT imaging on both the single-channel and multichannel applicator setups was
performed, and three treatment plans were created for each applicator setup. A
dose of 300 cGy was prescribed to various targets around the applicator surface:
plan no. 1 contained a symmetrical dose distribution, plan no. 2 targeted the upper
part of the applicator, and plan no. 3 targeted the lower part of the applicator. The
six treatment plans are shown in figure 8.13, with the radiopaque marker and
MOSkins (indicated by the red spheres) clearly visible.
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Figure 8.13 Sagittal views of the delivered plans containing various dose
distributions. Three plans prescribed to the single-channel applicator are shown on
the top images (a,b,c for plans 1, 2, 3, respectively), and three plans corresponding
to the multichannel applicator shown on the bottom (d,e,f for plans 1, 2, 3,
respectively).
Each plan was delivered three times, and at the end of the experiment MOSkins were
recalibrated. Calibration curves were adjusted to account for the change in detector
sensitivity using linear interpolation, and calibration factors were adjusted as a
function of the VTH reading prior to dose delivery.
One of the three dosimeters was damaged during removal from the probe, and
therefore could not be recalibrated. Without recalibration the resulting
discrepancies were too high, and the data has been omitted in the final analysis.
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Results and discussion

An example of online MOSkin dose readout (cGy) with respect to treatment time (s)
during a MVC applicator delivery is shown in figure 8.14. Dose contributions from
individual catheters can be observed from the response plateaus.

Figure 8.14 Response of two MOSkin dosimeters with respect to treatment time,
showing dose contributions of individual channels (indicated by dose plateaus)
within the MVC applicator.
Integral discrepancies were evaluated between measured, D!"!"#$ and planned,
D!"# doses in cGy, and evaluated according to:
ΔD % =

!!"!"#$ ! !!"#
!!"#

∙ 100

(8.9)

Mean discrepancies of 1.40 ± 0.37 % and 2.79 ± 1.27 % were calculated over the
three delivered plans and two dosimeters, for the single-channel and multichannel
applicator plans, respectively. Discrepancies ranged between 1.01 and 1.98 % in the
single-channel applicator setup, and between 0.83 and 4.27 % in the multichannel
applicator setup, with the planned dose always lower than the measured dose. The
mean error over all measurements was calculated as 2.09 ± 1.15 % (figure 8.15).
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Figure 8.15 Mean dose discrepancies for the single- and multi-channel applicator
experiments.
Errors attributed to MOSkin localization on the CT and measurement reproducibility
were evaluated. Localization uncertainty was determined as ±1 mm in the
longitudinal direction and ±0.5 mm in the coronal and sagittal directions. The effect
of this uncertainty on the dose varied for each plan, and was quantified as ± 3.62 %
on average. The highest difference in dose arising from the 0.5-mm error on the
coronal plane was 13 cGy. MOSkin reproducibility was quantified as 0.70 ± 0.33 %,
calculated as the variation in the measured dose between the three deliveries of
each plan (figure 8.16).
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Figure 8.16 Reproducibility of the measured integral dose for each MOSkin.
Mean integral dose discrepancy was 1.39 % lower for single-channel applicator
deliveries, as compared to the multichannel. This is a result of the higher dose
gradients present in multichannel applicator treatments, as shown by the planned
dose distributions on figure 8.13. Discrepancies may also arise from treatment
deviations in the SDD, as compared to the calibration position, where angular
and/or energy dependence may affect MOSkin response.
8.5.2.3

Conclusion

The in-phantom feasibility study has demonstrated successful DRP dose verification
to the rectal wall during vaginal HDR BT treatment delivery, both with the singlechannel and multichannel applicators. MOSkin dosimeters have indicated good
agreement with the planned doses, measurement reproducibility, and possibility of
incorporation into the regular treatment flow.
8.5.3 In vivo study
Following favorable feasibility study outcomes, the DRP was ready to be applied to
clinical patient treatments. The aims of the following study were to employ the DRP
to monitor rectal wall dose in vivo, for patients undergoing HDR BT treatments of
vaginal cancer; to calculate and compare discrepancies between planned and
delivered doses, and assess the potential causes of these discrepancies.
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Methods

A total of nine patients undergoing gynecological HDR brachytherapy of the vaginal
cuff and/or vaginal mucosa were recruited for the study. The cylindrical MVC
applicator of 30 or 35 mm in diameter was used in all cases, with a dose
prescription of 500-700 cGy to the PTV. Bladder filling was administered using a
transurethral Foley catheter, and treatment planning was carried out on pelvic CT
imaging of 3-mm slice thickness. The DRP was positioned inside the patient during
the implant insertion phase of the treatment, prior to imaging. It was removed
following dose delivery along with the applicator.
Patient para-transversal, para-sagittal, para-coronal and 3D CT images visualizing
the multichannel applicator and the DRP are shown on figure 8.17. The sensitive
volumes of the three dosimeters are marked by arrows and labeled A1, A2, and A3.
The large bright mass on the DRP is the radiopaque marker. Contoured OARs can be
seen on the bottom right image.

Figure 8.17 Para-transversal (a), para-sagittal (b), para-coronal (c) and 3D images
(d) on a patient CT. Three MOSkin dosimeters are visible and labeled in red as A1,
A2, and A3.
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Results

A total of 26 treatment sessions were monitored to comprise a total of 78 IVD
measurements. The measured doses DMOSkin (grey) and planned doses DTPS (black)
are shown on the frequency distribution in figure 8.18. The mean and standard
deviation were determined as 308.6 ± 99.4 cGy and 304.0 ±95.7 Gy for DMOSkin and
DTPS, respectively.

Figure 8.18 Frequency distribution of the measured and TPS dose ranges over all
IVD sessions.
The discrepancy between the measured and planned doses was calculated
according to equation 8.9. One of the treatments fractions showed dose
discrepancies ranging between -28.0 and -36.8 %, caused by longitudinal motion of
the DRP visible with the naked eye. This session was deemed an outlier, and was not
considered in the overall discrepancy evaluation. In another session a MOSkin
malfunction occurred, with the detector failing to accurately measure the dose due
to physical damage. Thus, 74 measurements were available for further analysis,
resulting in a mean ΔD of 2.2 ± 6.9 %. 44.6 % of the measurements were found to be
within ±5 % of the TPS dose values, 89.2 % were within ±10%, and 10.8% were
found to have a discrepancy exceeding ±10 %. Discrepancy results are plotted in
figure 8.19 in increasing order for the 74 measurements.
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Figure 8.19 ΔD values (%) plotted in increasing order for 74 of the measured rectal
wall doses.
|ΔD| distributions were evaluated with respect to detector positioning on the DRP
and the time elapsed between the imaging and dose delivery phases using the
Wilcox-Mann-Whitney U test (performed with Statistica v. 12, Statsoft, Tulsa, OK,
USA).
Correlation was established, showing the highest mean discrepancy of 7.8 ± 4.9%
for the most cranial detector (i.e., MOSkin #1), whereas the lowest dose discrepancy
of 3.9 ± 2.2% was determined for the most caudal detector (i.e., MOSkin #3). The
mean discrepancy of MOSkin #2 was 6.1 ± 3.6%. P-values for the differences
between |ΔD| values of MOSkins #1 and #2, #2 and #3, and #3 and #1 were
determined as 0.33, 0.14, and 0.002, respectively. Detector positioning and mobility
range on the DRP are shown in figure 8.20.

Real-time BT QA: In vivo dosimetry

106

Figure 8.20 MOSkin positioning and mobility range on the DRP with respect to the
applicator.
|ΔD| distributions with respect to MOSkin position on the DRP are shown in figure
8.21, where the rectangle corresponds to standard error and the bars correspond to
standard deviation.

Figure 8.21 Box plot |ΔD| distributions with respect to MOSkin position on the DRP.
Mean |ΔD| values were also found to be smaller for lower treatment planning times.
Time duration between imaging and dose delivery phases was divided into two
groups: group 1 of t ≤ 90 min and group 2 of t ≥ 90 min. Mean |ΔD| values for group
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1 and 2 were determined as 4.7 ± 3.6 % and 7.1 ± 5.0 %, respectively. A box plot of
these results is shown in figure 8.22 where the rectangle signifies standard error
and the bars correspond to the standard deviation.

Figure 8.22 Box plot |ΔD| distributions with respect to the time lapse between
imaging and dose delivery phases.
8.5.3.3

Discussion

In light of the increased discrepancies in dose with longer time duration between
planning and dose delivery phases, it is recommended that planning be kept as short
as possible.
It is important to note that TPS point-dose estimations were provided using patient
images following implant insertion, and no imaging was performed prior to dose
delivery or post-treatment. For this reason it is not possible to identify specific
reasons for discrepancies in individual cases, since a number of factors could
explain the difference between measured and estimated doses. These include:
1. Morphological changes in the OARs, especially the rectum where the DRP
was positioned, as well as the filling of the bladder, and muscle relaxation.
2. Shifting or rotation of the DRP prior to dose delivery.
3. Uncertainties attributed to MOSkin IVD and TPS dose estimation.

Real-time BT QA: In vivo dosimetry

108

An uncertainty budget has been estimated as ± 6.2% for MOSkin IVD using the DRP,
and is reported in Table 8.2. The highest contribution to measurement uncertainty
of ±4.5% was the distance dependence, followed by angular dependence with an
uncertainty of ±3%, and the other contributors of ≤1.5%.
Uncertainty (%, k = 1)
MOSkin calibration uncertainty
SK determination

±1.5

Phantom assembly, SSD, other TG-43 parameters

±1.0

Intrinstic MOSkin uncertainty
Reproducibility, temp. dependence, readout res.

±1.5

Change in MOSkin sensitivity with exposure

±1.5

Distance (energy) dependence

±4.5

Polar angle dependence

±3

Azimuthal angle dependence

±1

Total uncertainty

±6.2 %

Table 8.2 Uncertainty budget estimation for DRP IVD with MOSkin detectors.
TPS dose uncertainties have been estimated as ± 7.1 % including variables such as
TPS dose calculation, SK determination, dosimetric medium effects, and imagerelated uncertainties of applicator and MOSkin location registration. A conservative
discrepancy threshold of 10% is thus proposed for implementation in the clinic, in
which case both the estimated instrumental and TPS-dose estimation uncertainties
would remain within the margin of error.
Previous HDR BT IVD studies determined comparable uncertainties: Suchowerska
et al. (2011) found a maximum uncertainty of -9% for the 10 patients monitored
using scintillation detectors placed inside a urethral catheter [79]; Mason et al.
(2016) determined a mean plan uncertainty of 12.3 % in rectal wall MOSFET IVD
[153]; Seymour et al. (2011) found a ±20% agreement between 95% of the
measured and nominal doses using a diode array [122]; and Carrara et al. (2016)
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found integral point-dose uncertainties of 5.7% when incorporating MOSkin
dosimeters onto the TRUS probe to measure doses to the rectal wall [140]. More
specifically, estimated uncertainties using the DRP in gynecological treatments are
~1% higher than those reported for MOSkins mounted on the TRUS probe. This is
explained by the higher range of dwell positions on the longitudinal axis of the MVC
applicator, as compared to the needles in the prostate procedures, and thus the
presence of a wider polar angle during dose measurement. However, the range of
azimuthal angles is lower in gynecological treatments, as compared to prostate, and
thus azimuthal angle uncertainties are reduced by 1%.
The use of imaging either pre- or post- dose delivery would decrease positional
uncertainties of the IVD system. Carrara et al. (2016) determined a 1.5 % decrease
in dose discrepancies using the TRUS-integrated MOSkin IVD system when
comparing measured doses to those indicated on the post-treatment images, as
opposed to doses identified in the pre-treatment geometry. Additionally, a method
of securing the DRP inside the rectum, such as introducing fixations similar to those
incorporated into BT applicators, would also reduce positional shifts.
This study provides insight into an alternative method for rectal wall in vivo
dosimetry using MOSkin dosimeters, as opposed to the commonly used diode
detectors. Although diodes are more practical in that they do not require a
sensitivity adjustment throughout dosimeter lifetime, like MOSkins they exhibit
energy and angular dependence. In this study MOSkins have shown temperature
independence, and like other MOSFETs, they are integral dosimeters that store
measured dose. Moreover, MOSkin sensors in particular were developed to measure
absorbed dose at a 0.07 mm build up depth, making them especially suitable for
rectal wall dose measurement.
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Conclusions

The DRP has demonstrated the ability to verify integral dose in gynecological HDR
BT treatments in three points along the surface of the rectal wall. It showed ease of
incorporation into the established treatment flow, and overall method feasibility.
Most patients without rectal complications were eligible for DRP insertion, although
the procedure caused additional discomfort to the patient. In light of the results of
this study, it is recommended to minimize time between planning and dose delivery
to avoid compromising the accuracy of the delivered treatment as a result of
increased probability in positional shifts of the implant. Dose discrepancies within
±10 % can be recognized by the DRP system, but at this stage the system is not able
to identify the exact reason behind the detected error in dose.
This study has shown the possible ease of IVD incorporation into the current INT
treatment, and has presented a new IVD system utilizing small and practical MOSkin
dosimeters. These findings can be used to develop algorithms for error detection,
and to set relevant action levels in the case of detected discrepancies between
planned and measured rectal wall doses in gynecological BT treatments, to further
increase the safety and reliability of HDR BT.

Chapter 9
Real-time BT QA: Source tracking

9.1

Source tracking for treatment verification

Direct real time measurement of the radiation emitted by the HDR source can provide
information on its position, dwell time, and step size, and thus independently validate
that the source has been delivered as planned. A comprehensive source tracking
system, with spatial and temporal resolutions appropriate for HDR treatments, has the
ability to reconstruct both dwell positions and dwell times.
Previous methods of HDR source tracking have been heavily based on imaging:
utilizing arrays of ion chambers [154] and diodes [120, 155], as well as scintillation
[114], fiber coupled aluminum oxide crystals (Al2O3:C) [156], pixelated [121], and
diamond detectors [157]. Other imaging techniques adapted for HDR source QA
include MR [158], C-arm [159], x-ray fluoroscopy [160], autoradiography [161], flat
panel [113, 162-164], and fluorescent screen imaging [165], as well as radiochromic
film [166] and diode based Gallium Nitride (GaN) probes [114, 167, 168].
Radiochromic film measurements can only be used in the pre-treatment stage,
whereas MR imaging and autoradiography methods do not allow a temporal resolution
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above 2 seconds. Imaging modalities such as C-arm and co-RASOR require expensive
equipment that is not always available in clinics. Systems that have shown optimal
millimetric spatial resolution include the 2D diode array, Timepix pixelated detectors,
ion chambers, autoradiography, GaN probes, EPIDs, fluorescent screen imaging, and
radiochromic film when used in combination with photodiodes. The 2D diode array
proposed by Espinoza et al. (2015) has the ability to be read out in real-time as well as
allow source position and dwell time reconstruction with sub-millimeter and subsecond precision, respectively [120]. Wang et al. (2014) and Guiral et al. (2016) in
particular proposed to incorporate four GaN-based dosimeters into a commercial MVC
applicator for gynecological HDR BT treatments, resulting in sub-millimeter and subsecond HDR source tracking capability [167, 168]. However, the proposed method
utilizes four of the MVC applicator channels, and so limits the dose distribution
potential for gynecological treatments. Thus the need for a system that can verify the
source position, step size, and dwell time with sub-millimeter and sub-second spatial
and temporal resolutions in real-time remains.

9.2

Aim of this chapter

The aim was to develop a prototype of a multichannel brachytherapy applicator with a
verification system embedded around its surface, and verify the system’s suitability for
HDR BT source tracking in real time. The first step was to select and characterize diode
detectors and their packaging suitable for the system, and establish optimal
measurement settings, considering specific demands required by HDR BT treatments.
The second step was to assemble and calibrate the system, and the third step was to
evaluate the system’s performance by verifying its ability to reconstruct 192Ir dwell
positions and times using the defined methodology.
The diode characterization study has been submitted to the Journal of Physics as
Romanyukha, A.A., Carrara, M., et al., Preliminary epi-diode characterization for HDR
brachytherapy quality assurance.
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The system calibration and performance verification studies have been submitted to
Physica Medica Journal (invited paper) as Romanyukha, A.A., Carrara, M., et al., An
innovative gynecological HDR brachytherapy applicator system for treatment delivery
and real-time verification.

9.3

Detector characterization and definition of sensitive volume
thickness

The first step was to characterize the diode detectors selected for the system, and
establish optimal sensitive volume thickness and readout settings for measurement of
the 192Ir inside the BT bunker. Then the diodes’ dynamic range, temporal and spatial
resolutions, and method of dwell time reconstruction were defined, followed by the
investigation of source-strength dependence of the response for the range of SK used in
the clinic.
9.3.1 Materials
Measurements were performed in the CMRP lab and the HDR BT bunker at INT on two
sets of diodes containing different silicon chip thicknesses. The first set was tested
with the Nucletron microSelectron afterloader system, and the second set was tested
with the Flexitron afterloader system and a new treatment communication console
(TCC) recently commissioned at the INT BT facility.
9.3.1.1

Diodes and readout system

Diodes have been developed at the CMRP and assembled on a Kapton pigtail using the
“drop-in” technique [169] to reduce energy dependence. The selected diode probes
have a Kapton pigtail of 325 mm in length and contain the diode with a sensitive area
of 1.5 x 1.5 mm2 (figure 9.1).
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Figure 9.1 (a) Diode wire bonding covered in epoxy to increase detector
durability (b) Diode bonds and silicon sensitive chip (1.5 x 1.5 x 0.038 mm3), as
viewed under a microscope).
The first and second diode sets were p-type and n-type, respectively, and had silicon
layer thicknesses of 38 and 500 μm, respectively. The first set contained epitaxial (epi)
diodes with 0.1 kOhm-cm resistivity, and the second set contained bulk diodes with 5
kOhm-cm resistivity. A schematic of the p-type epitaxial diode topology with packaging
drop-in method patented and characterized at the CMRP [170] is shown in figure 9.2.
The n-type diodes used in this study are analogous in assembly and construction, but
with base thickness and resistivity of 500 μm and 5 kOhm-cm, respectively, in order to
increase sensitivity and improve the signal-to-noise ratio (SNR) for dose rate
measurement at larger distances between the 192Ir source within HDR BT needles and
the diode.

Figure 9.2 Schematic of the p-type epitaxial diode topology, taken from [170].
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These particular diodes have been selected for use with the HDR BT source due to
their radiation hardness, sensitivity, and passive mode real-time readout, minimizing
leakage current and guaranteeing suitability for in-patient use.
The readout system, also designed in the CMRP, functions by integrating the charge
over the window selected in the readout settings i.e. the integration time. The system
consists of an AFE0064 (analog front end) electrometer with 64 circuits for current
integration, an FPGA (field programmable gate array), and power supply boards. The
differential analog-to-digital converter ADS8363 communicates with the FPGA, while
the FPGA Xem 3001 has an embedded USB to transfer data from the reader to the PC.
Sensitivity of measurement can be adjusted by selecting the charge capacity and can
reach 9.6 pC per 1-kHz readout, corresponding to the number of times that the
capacitor discharges in each readout interval.
The reader has four channels and can accommodate up to four detectors at a time.
Proper grounding and shielding were ensured during detector and reader assembly,
including aluminum coverage to minimize radiofrequency noise (figure 9.3b). The
sensitive components of each diode were covered with a thin layer of Kapton and
epoxy in order to protect the exposed wire bonds and increase detector durability
(figure 9.1a).

Figure 9.3 (a) Reader containing four channels for simultaneous readout of four
diodes, and composed of three boards: AFE, FPGA, and power supply. (b) Reader
assembled and covered in aluminum, with two diodes connected.
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A number of readout settings can be adjusted to suit the particularities of the HDR
source, especially when a wide range of dose rates is involved. The range setting is
between 0 and 7, and corresponds to maximum charge values of 0.13 and 9.6 pC,
respectively, to be integrated at each readout step. The Histogram readout software
(figure 9.4) displays both the instantaneous (top) and integral (bottom) responses in
each of the four channels. Diode readout in channel 3 is shown, along with settings
such as the integration time, readout frequency, and acquisition time that can be
adjusted for each measurement.

Figure 9.4 Histogram software displaying the instantaneous (top) and integral
(bottom) responses of a diode reading in channel 3.
The instantaneous response is expressed as a fraction of the full scale of charge
permissible by the corresponding range setting, and measured as the percentage of the
total AFE capacity occupied by the measured raw counts CRAW. The response at the
selected readout frequency is then converted into the total charge by multiplying the
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detected true counts CTRUE by the corresponding maximum charge of the range setting
(pC), where CTRUE is obtained according to equation 9.1:
C!"#$ =

!!"#
!""#"

∙ 100

(9.1)

The frequency of each step can range between 1 and 1000 Hz, and the integration time
can be set between 50 and 400 μs.
9.3.2 Methods
The thickness of the sensitive silicon chip of the diode impacts the dynamic range of
detector signal with respect to HDR source position. The first set of diodes contained
silicon chips with a thickness of 38 μm, aimed to provide a high spatial resolution and
reduce response averaging.
9.3.2.1

I-V characteristics

In order to verify low noise and a constant relationship between applied voltage and
diode current prior to assembly and shielding, current-voltage (I-V) characteristics
were measured by applying up to 30 V in various increments. P-type epi-diodes (38
μm) and n-type bulk diodes (500 μm) were tested, and their I-V responses are shown
in figure 9.5.

Figure 9.5 Example of obtained I-V characteristics of p-type (38-µm) and n-type (500µm) diodes.
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Kapton pigtails of the detectors were assembled with three-pin female connectors, and
aluminum shielding was added around the entire dosimeter to minimize noise and
eliminate the detectors’ sensitivity to light.
9.3.2.2

Definition of sensitive volume thickness

The main parameters for evaluation of diode suitability for HDR BT source tracking
were defined as:
1. Dynamic range of the diode.
2. Spatial resolution.
3. Temporal resolution.
4. Effect of dose rate on diode response at SK range of 10 - 45 mGy.m2.h-1.
These parameters were evaluated by positioning the detectors inside a water
equivalent plastic phantom at a distance of 3 mm from the catheter, where the HDR
source will travel on the longitudinal axis (figure 9.6). The smallest step size of 2.5 mm
and dwell times of 2 seconds were selected and delivered with the microSelectron
afterloader unit. The source was sent to dwell in all 48 available dwell positions inside
the catheter.

Figure 9.6 Setup of the diode characterization measurements.
Optimal readout settings were determined in the BT bunker to account for specific
noise characteristics of the treatment theater by modifying the settings of readout
frequency, integration time, and range. Diode range as a function of SK was investigated
by acquiring diode response for SK values between 38.0 and 13.2 mGy.m2.h-1.
9.3.3 Results
Diode signal for integration times of 200, 300, and 400 μs, respectively, is plotted in
figure 9.7. The highest permitted integration time of 400 μs was selected as optimal in
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order to achieve maximum detector sensitivity. The last sharp peak in all three curves
visualizes the retraction of the HDR source into the afterloader.

Figure 9.7 Variation in diode response (pC) for selected integration times of 200, 300,
and 400 μs.
Dynamic range was determined as the number of discriminated dwell positions
multiplied by the source step size, and was assumed to extend until 95% of the binned
data points in each cluster no longer conformed to their corresponding cluster group
(i.e., dwell position response range (pC)), within two significant figures. Diode
response binned into 0.05-s clusters is shown in figure 9.8, with the peak
corresponding to the closest dwell position to the diode sensor. The difference in the
SNR in two different SDDs is shown by the inserts.
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Figure 9.8 Diode response (pC) as a function of irradiation time (bin frequency=0.05 s).
SNR for two SDDs is shown in the imbedded figures.
Diode response, normalized for SK, is plotted as a function of treatment time with range
settings of 4, 5, and 6 and SK of 25.4 mGy.m2.h-1 in figure 9.9. Range settings of 4 and 5
have shown to be insufficient as diode response oversaturates before the source
reaches the closest available dwell position with respect to the center of the diode.
Range 6 or higher was therefore determined optimal in order to accommodate the
wide range of dose rates utilized in the clinic.
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Figure 9.9 SK-normalized mean diode response in each dwell position as a function of
treatment time (s) for readout range settings of 4, 5, and 6.
Diode response as a function of 192Ir source strength is shown in figure 9.10 with the
three curves corresponding to source strengths of 13.2, 34.6 and 38.0 mGy.m2.h-1.
Figure 9.10a shows the total diode response in terms of collected charge with respect
to treatment time, where the highest range of charge corresponds to the highest SK
value of 38.0. In figure 9.10b the same three curves normalized for SK are plotted. For a
large variation in source strength (i.e., -26 mGy.m2.h-1) some diode dependence on the
dose rate can be observed. Normalized diode response appears overall stable for
source positions located at ±12.5 mm, whereas for dwell positions located further
away the response changes due to lower SNR at lower activities.
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Figure 9.10 Total (a) and SK-normalized (b) diode response for various source
strengths.
Diode dynamic range with respect to source distance from the center of the diode
sensitive volume is plotted in figure 9.11. Diode response peaks at a SDD of 0 mm (i.e.,
when the source dwell position is directly above the diode), and decreases in both
directions as the source moves away. Dynamic range for diodes 1, 2, and 3 was
determined as ±20 mm, ±18 mm, and ±17 mm, respectively. Fluctuation of diode
response in a single dwell position was quantified as 0.5 - 2.6% for diode 1, 0.3 - 1.3%
for diode 2, and 0.9 - 3.0% for diode 3, increasing with SDD. The error bars on both the
x- and y-axes are too small to be visible on the plot.
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Figure 9.11 SK-normalized diode response as a function of SDD.
Source dwell time can be determined from the plateaus in diode signal, shown in figure
9.12, where each plateau corresponds to a dwell time of 2 seconds for each dwell
position.

Figure 9.12 Diode response plateaus, corresponding to individual dwell positions.
The dwell time is calculated as the ratio of the number of measurements in each
plateau and the frequency of readout, and was verified with an accuracy of ± 0.3 s, as
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compared to the nominal dwell time indicated by the TCC. Moreover, source transit
time can be observed, and is represented by single points between the plateaus in
figure 9.12. It is shown in more detail in figure 9.13, showing diode response with
respect to treatment time in a single dwell position. Source transit time is visualized
before and after the source reaches the dwell position, traveling past the diode in both
directions. The source transit time was calculated as 0.3 s both as it traveled from the
afterloader to the planned dwell position and as it retracted back, for a total of 0.6 s in
transit.

Figure 9.13 Time contribution of the source transit, represented by the two response
peaks.
9.3.4 Conclusions
Diode response has been evaluated with respect to various measurement settings of
the reader and readout software, as well as the treatment parameters such as source
step size, dwell time, and range. A balance between minimal noise and maximum diode
sensitivity can be obtained using the established measurement settings, and spatial
and temporal resolutions required for HDR BT source tracking in the clinical range of
192Ir

SK values. A method for dwell time calculation has been formulated and tested to

show a ± 0.3 s agreement with the TCC.
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The dynamic range of the epi-diodes indicated that approximately 40 mm of
gynecological applicator coverage can be obtained, which in some cases may be
shorter than the clinically relevant region of ~50 mm.
9.3.4.1

Change of HDR afterloader

It is important to note that following this stage of the study the microSelectron
afterloader was replaced with the Flexitron (Elekta Brachytherapy, the Veenendaal,
NL) afterloader at the INT BT facility.
The Flexitron afterloading unit contains 40 transfer tube connections, allows a minimal
step size of 1 mm, positional accuracy of ± 0.5 mm and a minimum dwell time of 0.1
seconds. The 192Ir source (Flexisource, Elekta) core is 3.5 mm (i.e., 0.1 mm smaller than
in the microSelectron unit). The TPS is the corresponding version of Oncentra Brachy.
9.3.5 Higher sensitivity diodes
In order to extend the dynamic range of the diodes, new detectors were developed,
increasing the thickness of the silicon sensor to 500 μm, and thus increasing photon
detection. Measurement settings were modified to accommodate the higher diode
sensitivity with range and integration settings of 7 and 200 μs, respectively, and
readout frequency kept at 1 kHz.
9.3.5.1

Methods

Three diodes were used to investigate dynamic range as a function of temporal and
spatial resolutions by varying the dwell time and source step size between positions.
The new Flexitron afterloader system allowed diode spatial resolution to be tested at a
1-mm step size, as opposed to the 2.5 mm permitted by microSelectron in the previous
measurements. Diodes were positioned inside a water equivalent phantom and the
source was sent to dwell positions of 288-100 mm at step sizes of 1, 2, and 3 mm,
maintaining the same measurement setup shown in figure 9.6. To obtain 100 data
points for each of the selected temporal resolutions of 0.1 and 0.2 seconds,
respectively, dwell times of 5 and 10 seconds were used for statistical accuracy.
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Results

Diode range as a function of temporal resolution is plotted in figure 9.14, where data
bins of 0.05 and 0.1 s correspond to temporal resolutions of 0.1 and 0.2 s, respectively.
For a step size of 1 mm and a temporal resolution of 0.1 s the mean diode range was 69
± 3 mm, increasing to 109 ± 5 mm and 138 ± 9 mm for 2 and 3-mm step sizes,
respectively. For a temporal resolution of 0.2 s and a 1-mm step size a range of 87 ± 3
mm was determined, increasing to 133 ± 5 mm and 176 ± 6 mm for source step sizes of
2 and 3 mm, respectively. To accommodate the temporal and spatial resolutions of 0.1
s and 1 mm, respectively (i.e., the accuracy permitted by the afterloader device), a data
bin size of 0.05 s was selected. Readout frequency of 1 kHz was used in order to obtain
100 readouts for each 0.1-second period.

Figure 9.14 Dynamic range of the diodes as a function of temporal resolution (i.e.,
measurement bin size), and spatial resolution (i.e., source step size).
Dosimeter characteristics of both diode sets are reported it Table 9.1. Diode ranges are
reported as mean values over the three diodes tested in each set.
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Set no. 1

Set no. 2

Type

p-type

n-type

Resistivity

0.1 kOhm-cm

5 kOhm-cm

Si chip volume (mm3)

1.5 x 1.5 x 0.038

1.5 x 1.5 x 0.5

Katpon pigtail length (mm)

325

325

Range

6

7

Integration time (μs)

400

200

Frequency (kHz)

1

1

SK (mGy.m2.h-1)

25

37

Source step size (mm)

2.5

2

Dwell time (s)

2

0.2

36 ± 4

133 ± 5

Readout settings

Dynamic range measurement

Dynamic range (mm)

Table 9.1 Characteristics of the two sets of epitaxial diodes.
9.3.5.3

Conclusions

The dynamic range of the sensitive diodes was found to extend 97 mm further than in
the first set, and thus coverage of the top 50 mm of the applicator can be achieved.
These results were then used to determine optimal diode positioning on the surface of
the multichannel applicator prototype, allowing temporal and step size resolutions of
0.1 s and 1 mm, respectively.

9.4 The source tracking system and calibration
The next step was to assemble and calibrate the proposed system by defining the
relationship between the fixed position diode response and source location, with
respect to a reference point.
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9.4.1 The proposed system
A gynecological multichannel applicator was designed based on the commercially
available Vaginal CT/MR Multi Channel Applicator (Elekta Brachytherapy, TH
Veenendaal, NL). The applicator prototype is 30 mm in diameter and contains seven
peripheral and one central channel, with the possibility of inserting an intrauterine
tube when required for the treatment. The prototype was produced at UOW using
water-equivalent plastic. To accommodate three detectors on the surface of the
applicator, dedicated grooves were made between peripheral channels 1 and 7, 3 and
4, and 5 and 6. The three diodes were positioned at 35, 37, and 39 mm from the
applicator tip, respectively (figure 9.15a), to ensure coverage of the top 50 mm. In
order to simulate radiation interactions inside the patient and provide adequate
scattering conditions, a phantom of 160 x 220 x 160 mm3 was fabricated using the
same water equivalent material to surround the applicator without any air gaps (figure
9.15b). Plastic catheters with a diameter of 2 mm and an external length of 293 mm
(i.e., “catheter with collar 6F”) were placed in the peripheral channels and the reusable
Intravaginal CT/MR Tube was placed in the central cavity.
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Figure 9.15 Cylindrical multichannel applicator with three diodes positioned around
the surface of the applicator (a). Custom-made water equivalent phantom to surround
the applicator (b).

9.4.2 System calibration
A calibration of the system was required in order to establish a method for dwell
position reconstruction at any given time of the treatment, with respect to a reference
point and fixed locations of the three detectors on the applicator.
The location of the first dwell position in each of the eight channels in the applicator
was determined using GafChromic film measurements. The film was wrapped around
the applicator surface with the edge of the film aligned to the tip of the applicator. The
distal tip of the applicator (with respect to the afterloader) was chosen as the
reference point for determining the source location within the applicator. The first
dwell position in the central catheter was measured using a separate strip of film. A
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total of three dwell positions per catheter, located at 50 mm apart, were delivered to
ensure precision of measurement. Position locations exposed on the GafChromic film
were evaluated using a Matlab script to determine the center of each

192Ir

exposure

and its location with respect to the edge of the film (figure 9.16). The distances (mm)
from the applicator surface, ± 0.1mm (k=1), were 7.1 mm, 6.9 mm, 6.8 mm, 7.1 mm, 6.9
mm, 6.5 mm and 6.5 mm, for the peripheral catheters 1 to 7, respectively. The first
dwell position in the central catheter was set as 5.5 mm (taken from the Elekta user
manual).

Catheter

d from the tip (mm)

1

7.1

2

6.9

3

6.8

4

7.1

5

6.9

6

6.5

7

6.5

Central

5.5

Table 9.2

Figure 9.16 GafChromic film measurement results. The location of the first dwell
position in each catheter is reported in table 9.2, as the distance d, ±0.1 mm (k=1),
from the applicator tip.
In every catheter each dwell position was characterized by its specific diode response
with respect to the reference point. A combination of two diodes was employed for
each catheter. The source step size was selected as 1 mm, and the source was sent to
dwell positions of 288-100 mm in the peripheral channels and 300-100 mm in the
central channel, respectively, for a dwell time of 1 second in each position.
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The acquired diode response was divided by SK at the time of measurement, and
plotted as a function of distance from the applicator tip (mm) established with the
GafChromic film. Mean diode response was plotted with respect to its location from the
reference point. The highest responses of two of the three diodes per catheter were
fitted with multi-term Gaussian functions. The two diodes, number of Gaussian terms
per fit, and the corresponding R2 values for each catheter are reported in table 9.3. DHR
and DLR correspond to the high and low response diodes in each catheter, respectively.
The two-diode combinations of Gaussian functions for each catheter are shown in
figure 9.17. The Gaussian terms for each catheter are provided in Table 9.4.
Catheter

Diodes

No. of Gaus. terms

R2 values

DHR

DLR

DHR

DLR

DHR

DLR

1

D2

D3

4

3

1

0.9998

2

D2

D3

4

3

1

1

3

D3

D2

4

2

1

0.9998

4

D3

D1

4

2

1

0.9998

5

D1

D3

4

2

0.9995

0.9999

6

D1

D2

3

2

0.9999

0.9998

7

D2

D1

4

2

1

0.9998

Central

D1

D3

3

3

1

1

Table 9.3 The diodes, number of Gaussian terms per fit, and corresponding R2 values
for each catheter.
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DIODE # Gaus term

D1

D2

D3

C.4

C.5

C.6

C.7

CENTRAL

a1

9.25

12.31

40.42

7.88

10.29

b1
c1
a2

36.97
12.78
8.46

41.99
3.76
15.64

36.23
4.73
42.47

36.49
11.22
10.06

36.81
10.76
-5.69

b2
c2
a3

36.96
33.41

51.66
15.12
64.17

36.09
10.26
12.53

36.47
29.36

59.02
21.09
13.78

b3
c3
a4

37.73
6.85
35.12

36.70
28.64

b4
c4
a1
b1
c1
a2

42.13
21.98
50.19
36.98
4.39
52.09

0.59
36.28
4.06
6.38

2.94
36.41
13.81
6.14

5.54
35.58
12.13
7.38

0.20
16.57
4.20
25.19

b2
c2
a3

36.79
9.11
0.68

36.25
10.15
9.77

36.63
34.94

35.76
31.51

36.91
11.55
15.80

b3
c3
a4

20.76
3.40
12.56

35.91
20.97
1.97

37.05
5.96
9.12

b4
c4
a1

36.88
26.25
0.63

74.61
441.30
2.54

37.37
30.38
55.32

0.00

5.97

5.63

b1
c1
a2

33.97
3.34
5.39

38.88
6.52
7.03

39.26
4.10
18.58

38.53
0.05
16.48

39.14
12.95
7.54

39.08
9.81
3.88

b2
c2
a3

34.17
34.37
2.82

38.93
34.59
10.11

39.20
15.17
47.66

39.61
6.21
24.09

39.45
32.57

40.05
44.28
9.25

b3
c3
a4

33.78
11.88

38.51
13.75

39.27
7.94
5.86

39.55
12.01
9.10

39.62
38.86

40.05
31.35

b4
c4

C.1

132
C.2

C.3

44.33
30.96

39.19
18.45

Table 9.4 Gaussian terms for the two diodes with the higher signals in each catheter.
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Figure 9.17 Multi-term Gaussian functions for each applicator catheter.
A schematic of the central channel calibration is shown in figure 9.18. The crosssectional horizontal view (a) of the applicator shows the 192Ir source (red sphere) in
the central channel, and the three diodes around it. Diode response is plotted as a
function of the source distance from the applicator tip (b), and in this case the diodes
with the highest response (i.e., diodes 1 and 3) were used for position and dwell time
reconstruction. The source in the first catheter dwell position is shown in the crosssectional longitudinal view (c) with diodes 1 and 2 fixed around the applicator
perimeter.

Figure 9.18 Schematic of the central channel calibration.
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9.4.3 Application of method
Thus at any given treatment time the two higher responses R1 and R2 of the three
diodes are divided by the source SK and used to solve for the source position d in the
given catheter, at the 95% CI as follows:

R ! pC = a! ∙ !

(

!!!! !
)
!!

+ a! ∙ !

(

!!!! !
)
!!

…

(9.2)

The diode with the high response will be used to derive two Gaussian solutions of the
source position, and the diode with the lower response will be used to determine
which of the two solutions is the real source position.
Figure 9.19 provides an example of dwell position reconstruction in a single catheter:
catheter-specific Gaussian equations are solved for source position using the highresponse diode, in this case diode 1 (D1), to derive positions (d1, d2) of (61, 14) and
(65, 13.5) for the two dwell positions. Corresponding (d1, d2) are also determined for
the low-response diode diode 2 (D2). In each case, the two D1 and D2 solutions that
are closer together (i.e., d2) for both dwell positions, shown on the lower part of the
plot, indicate the real position of the source, and correspond to 14 and 13.5 mm from
the applicator tip, respectively.

Figure 9.19 Example of the reconstruction of two dwell positions in a single catheter.
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Discussion

All catheters are characterized by a high- and a low-response diode, with the exception
of catheter 2 and the central catheter (as seen on the catheter-specific Gaussian fits in
figure 9.17). Since the applicator has 7 peripheral channels and three diodes
positioned between them, one catheter (i.e., Catheter 2) was characterized by a
response of the same magnitude from two diodes. The dynamic range of the diodes in
this case was to the order of 70 mm, as in the rest of the peripheral channels, and thus
unaffected. The central catheter is located at a 14-mm depth on the axial plane, and
since all diodes are positioned further away, the dynamic range was determined as 60
mm, and is thus lower than in the rest of the catheters.
In the case of source step size of ≤ 3 mm an increased uncertainty was observed in the
reconstructed source position for dwell positions directly perpendicular to the diode’s
sensitive chip. Since the diode sensitive area is 1.5 x 1.5 mm2 an identical diode
response may result in two consecutive dwell positions. In this case the diode with the
lower response, when positioned at a sufficient distance from the high-response diode,
can be used to distinguish such dwell positions.

9.5 Source tracking system verification
The final step was to verify the system’s ability to reconstruct 192Ir dwell positions and
times using the defined methodology. The first step of the verification was to test the
feasibility of reconstructing equally spaced dwell positions and simple dwell times,
followed by the retrospective delivery and reconstruction of 10 patient treatments
previously administered at INT.
9.5.1 Verification using simple dwell positions
The calibration established in section 9.4 was tested and verified for multiple
consecutive dwell positions within each catheter.

Real-time QA: Source tracking
9.5.1.1

137

Methods

Seven and eight dwell positions were delivered in the peripheral and central catheters
for a total range of 60 and 70 mm, respectively, at a step-size of 10 mm and a dwell
time of 5 seconds in each position. Dwell positions and dwell times were reconstructed
in each catheter using the described method. The absolute differences Δp and Δt
between nominal and measured dwell positions and times, respectively, were then
computed for every source position according to Δp = pmeas - pnom and Δt = tmeas - tnom.
9.5.1.2

Results

Reconstructed positions ranged between 6.45 and 67.10 mm from the applicator tip in
the peripheral catheters, and between 5.5 and 75.5 mm from the tip in the central
catheter. Mean Δp and Δt were –0.2 ± 0.5 mm and -0.1 ± 0.1 s (k=1), respectively. 50%
and 95% of absolute positional discrepancies were within 0.4 mm and 1.3 mm,
respectively, whereas 50% and 95% of absolute time discrepancies were within 0.1 s
and 0.4 s, respectively. The full list of mean discrepancies per catheter is reported in
table 9.5.
Catheter Discrepancies
CATHETER

Δp (mm)

Δt (s)

1

-0.2 ± 0.3

-0.2± 0.1

2

0.0± 0.4

-0.2± 0.1

3

-0.1± 0.4

-0.2± 0.1

4

-0.5± 0.6

-0.1± 0.2

5

-0.3± 0.5

-0.1± 0.0

6

-0.1± 0.5

-0.2± 0.2

7

-0.6± 0.5

-0.1± 0.1

Central

-0.1 ± 0.3

-0.1± 0.0

Mean ± SD

-0.2 ± 0.5

-0.1 ± 0.1

Table 9.5 Mean discrepancies in the reconstructed dwell position (mm) and dwell time
(s) reported for each catheter inside the applicator.
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The dwell time discrepancy ranged between 0 and -0.5 seconds. A discrepancy of ≤ 0.6
seconds is accounted for by the source transit, as shown in figure 9.13.
Dwell position discrepancies exceeding 1 mm were calculated in three instances in the
peripheral catheters. In catheters 4 and 7 Δp of 1.6 and 1.7 mm were determined at a
distance of ~67 mm from the applicator tip, where the accuracy of dwell position
reconstruction was compromised by the SDD. In catheter 5 a Δp of 1.3 mm was
determined at approximately 37 mm from the applicator tip, and is explained by the
physical constraints of the detector discussed in section 9.4.3.1. A similar trend was
found in the central catheter at 35.5 mm from the applicator tip, with the highest Δp of
0.7 mm reported in this position.
The results of the delivered verification plan are shown in figure 9.20, where the
nominal values (pink) and the reconstructed positions (blue) are plotted with respect
to treatment time (s). Individual dwell positions are visualized as plateaus in the
source position i.e. distance from the tip of the applicator.
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Figure 9.20 Reconstructed and nominal dwell positions for each delivered catheter.
9.5.1.3

Conclusions

The system has demonstrated sub-millimeter and sub-seconds positional accuracies,
respectively, in the simple dwell position and dwell time plans. The next step of the
study was to use increase treatment complexity by retrospectively delivering and
verifying real patient plans.
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9.5.2 Retrospective verification of patient treatments
A total of ten treatments previously administered to patients undergoing adjuvant
vaginal cuff BT after hysterectomy at INT and employing the 30-mm MVC, were
randomly selected from the database, and delivered and verified using the MVC
system.
9.5.2.1

Methods

Ten BT treatments were delivered in-phantom (figure 9.21), and then reconstructed
and compared to the nominal data provided by the TPS. Overall, 181 and 106 dwell
positions for the source dwelling in the central and in the lateral catheters,
respectively, were planned.

Figure 9.21 Setup of the retrospective patient plan delivery.
An example of a delivered plan is shown in figure 9.22. In this instance the central
channel contains 10 dwell positions at 290-245 mm, and all seven peripheral channels
are used to deliver three dwell positions at 288, 283, and 278 mm of varying dwell
times. The total dwell times per channel are indicated at the top of the plan.
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Figure 9.22 An example of a patient plan retrospectively delivered and reconstructed
using the system.

9.5.2.2

Results

An example of a plan reconstruction is shown in figure 9.23, where the reconstructed
(blue) and nominal (pink) dwell positions with respect to treatment time are displayed
for the central and six peripheral channels employed in the treatment. The treatment
begins in the central catheter’s furthest position from the applicator tip, delivering a
total of 16 dwell positions. At 222.3 seconds the central channel delivery is completed
(marked by the red arrow). The source then proceeds to two dwell positions 5 mm
apart in peripheral channel 2 for 34.1 and 11.8 s in duration, respectively, and one
dwell position in channel 3. The source then dwells in two positions in channel 4, 1 mm
apart and lasting 33.7 s and 11.3 s, respectively, and then to one dwell position in
consecutive channels 5, 6, and 7 for dwell times of 33.0 s, 21.7 s, and 33.3 s,
respectively.

Real-time QA: Source tracking

142

Figure 9.23 Example of treatment delivery verification with nominal positions and
dwell times shown in pink, and the reconstructed plan shown in blue.
Discrepancies between the nominal and reconstructed dwell positions and dwell times
for all 10 delivered plans are plotted in figure 9.24, with each data point corresponding
to one dwell position. The mean positional discrepancy was determined as 0.2 ± 0.4
mm and 0.0 ± 0.8 mm (k=1) for the central and lateral catheters, respectively. The
mean dwell time discrepancies are -0.1 ± 0.2 s and -0.0 ± 0.1 s (k=1) for the central and
lateral catheters, respectively. 50% and 95% of absolute positional discrepancies |Δp|
were < 0.3 mm and < 0.8 mm, respectively, for the source dwelling in the central
catheter, and < 0.5 mm and < 1.5 mm, respectively, for the source dwelling in the
peripheral catheters. Overall, 96.2 and 77.9% of absolute positional discrepancies
were < 1 mm for the central and peripheral channels, respectively.
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Figure 9.24 Planned (red squares) and measured (blue dots) dwell positions (a) and
times (c) for the central catheter, respectively, and between planned and measured
dwell positions (b) and times (d) for the lateral catheters, respectively, in the 10
delivered clinical patient plans.
50% and 95% of absolute dwell time discrepancies |Δt| were < 0.05 s and < 0.40 s,
respectively, for the source dwelling in the central catheter, and < 0.05 s and < 0.20 s,
respectively, for the source dwelling in the peripheral catheters.
9.5.2.3

Discussion

In this study, an innovative prototype of a MVC applicator with embedded diode
detectors was produced. Preliminary measurements on a “simple” and on ten different
clinical treatment plans have demonstrated the MVC system’s ability to monitor the
HDR source throughout the entire dose delivery phase, providing in vivo and real time
QA of the delivered treatment by comparing it to the prescribed plan. The system is in
principle able to detect errors in dwell position and dwell times, including
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spontaneous afterloader malfunction, incorrect applicator and indexer lengths,
mistakes in transfer tube connections, source calibration, and administration of the
incorrect treatment plan. The proposed pre-calibrated MVC system is the first
prototype of the MVC applicator with embedded diode detectors that is able to provide
dwell positions and times in real time with generally sub-mm and sub-second
accuracy.
The MVC system can be pre-calibrated via a relatively easy method, and source
positions and times can be obtained in real time without any assumptions or particular
dose distribution calculations within the applicator/patient. Source positions are
constrained along the central and peripheral catheters by the applicator, and the
diodes have fixed positions with respect to the catheters. Thus, for each possible
source position in one of the eight treatment channels, a unique solution exists from
the combination of the two dosimeters with the highest responses. This solution can be
determined experimentally prior to the use of the applicator and is valid without
further recalibration in the case of stable diode response. Moreover, specific
corrections for the possible energy and angular dependences of the diodes were not
necessary, because the overall diode response was taken as reference and intrinsically
modeled with the multi-term Gaussian functions.
This is different to systems that are not built-in with the applicator, such as 2D arrays
[154] or EPIDs [171], where more complex assumptions, pre-calibrations and
calculations have to be performed to accurately reconstruct source positions inside the
patient (for example complex algorithms, such as triangulation, and accounting for the
response lag in the case of EPIDs). Source localization performed using plastic
scintillation detectors benefits from their high sensitivity, angular and energy
independence (as opposed to diodes), and small size that allows them to be
incorporated into the treatment procedure. However their biggest drawback is the
mandatory stem signal correction.
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For the proposed system, it is imperative that calibration takes place in the same
conditions that are present during treatment. Moreover, the diodes are incorporated
directly over the dose delivery instrument, eliminating the need of additional steps in
the existing treatment procedure for the radiation oncologist. Prior to patient
irradiation the diode detectors must simply be connected to the readout system. To
fully integrate the system into the QA workflow, the readout system should be
connected with the afterloader treatment console for direct comparison between
nominal and measured (calculated directly on the console) dwell positions and times.
Wang et al. (2014) [168] and Guiral et al. (2016) [167], who also equipped a
commercial MVC applicator with four [GaN-based] dosimeters, presented results that
mainly address the discrepancies within the central catheter. Mean dwell position and
time discrepancies presented in the above studies are comparable to the results
obtained with the diode MVC system. In particular, the discrepancies were -0.11 ± 0.7
mm and 0.2 ± 0.4 mm (k=1) for dwell positions in Guiral et al. (2016) and in our study,
respectively, and 0.05 ± 0.09 s and -0.1 ± 0.2 s (k=1) for dwell times, respectively. In
our study, it was additionally shown that comparable accuracies can also be obtained
for lateral catheters on ten clinical treatments, with resulting dwell position and time
discrepancies of 0.0 ± 0.8 mm and -0.0 ± 0.1 s (k=1), respectively.
This study clearly shows potential for future use of the proposed system in the clinical
routine. The diodes can be integrated into commercially available MVC applicators of
any diameter, utilizing applicators that are already clinically approved and familiar to
hospital staff. A source detection range of the proximal 60-70 mm of the vagina is
sufficient for the majority of clinical applications of adjuvant vaginal cuff BT following
hysterectomy, where the proximal 3-5 cm of the vagina are normally treated [172]. An
increased number of diodes and their optimal positioning over the applicator could
further extend the range. The temporal and spatial resolutions are also in principle
sufficient, and would already allow the detection of significant delivery errors. A
thorough evaluation of the system’s ability to detect specific treatment errors will be
conducted in the future.
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An intrinsic limitation of the developed method is that the source tracking system is
incorporated directly on the MVC applicator, and thus is not able to detect shifts in
applicator position and rotation throughout the treatment, in particular with respect to
the planned target volume and the surrounding organs at risk. The use of the system
will therefore validate that the delivered treatment is in accordance with the planned
one, but no conclusions can be drawn about the delivered dose distribution. In vivo
dose measurements in the urethra or rectum [97, 114, 117, 173-176] will be necessary
to provide a comprehensive verification of the delivered treatment. Further in vivo
measurements are required to validate a potential combination of dosimetry and
source tracking methods.

9.6

Conclusions and recommendations

The applicator prototype with embedded diodes for HDR source tracking has shown
great potential for both treatment delivery and real-time BT treatment verification by
demonstrating a sub-second temporal resolution for dwell time verification and a submillimetric positional accuracy in 96.2 and 77.9% of reconstructed dwell positions in
the central and peripheral channels, respectively.
The proposed system is able to detect treatment errors relating to source position and
dwell time inside the applicator, such as the administration of the wrong treatment
plan, spontaneous afterloader malfunction (altering the source step size or dwell time),
mistake in the indicated indexer length, and systematic errors such as those occurring
as a result of incorrect source calibration.
The MVC HDR BT verification system can be improved in future studies by placing
additional diodes on the applicator surface as well as positioning detectors at a higher
distance from one another on the longitudinal plane to decrease uncertainties in close
proximity to the diode’s sensitive volume. Future studies to evaluate the MVC system’s
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ability to detect specific treatment errors and to investigate the possible combination
of the MVC system with in vivo dosimetry methods will be conducted in the future.

Chapter 10
Retrospective and real-time dosimetry:
recommendations and conclusions

10.1 Retrospective dosimetry
Solid-state semiconductor dosimetry has been successfully applied to the
visualization and spatially resolved dose rate measurement of intact sediment
samples, both artificially produced and natural samples, from key archeological and
hominin sites. The proposed Timepix methodology allows the measurement of
samples resinated as per micromorphology procedure, preserving the
microstratigraphic context of the sample during burial. A superior spatial resolution
of sample environmental dose rates that is well within the 3-mm beta particle range
has been achieved.
High dose rate inhomogeneity has been shown within the sample from the Liang
Bua Cave, while dose rates within the Denisova Cave sample have demonstrated
higher spatial uniformity and a normal dose rate distribution. Based on the results,
radioemitter inhomogeneity may affect sample age by up to 70%.
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Future studies employing the Timepix for sediment measurement have the potential
to achieve a 3D visualization of dose rates within samples by measuring thinner
slices. Dose rate calibration can be improved to further minimize dose rate
conversion errors. Energy calibration of the Timepix can be applied to evaluate the
energy deposition of detected particles, and explore the use of this feature for
isotope identification. Furthermore, Timepix measurement results can be modeled
using the Geant4 simulation platform to assess the effect on the dose absorbed by
the detector grains, and obtain a distribution of singe-grain ages.
This study is an important step towards improving the accuracy and precision of
chronology in both geological and archeological contexts, which can ultimately
deepen our knowledge on the evolution and dispersion of humankind.

10.2 Real-time dosimetry
The combination of in vivo dosimetry and HDR source tracking systems investigated
in this thesis have the potential to detect errors that would remain unknown
without real-time or post-treatment verification. The precision of the source
tracking system, which is able to provide excellent QA of the BT source throughout
the entire procedure, in combination with point-measurements of absorbed dose in
OARs, can be used in real time to prevent or provide awareness of a multitude of
potential missteps in gynecological HDR BT treatments. Epi diodes in the proposed
HDR source verification system are able to detect errors such as source calibration,
spontaneous afterloader malfunctions, incorrect applicator or indexer lengths, and
misconnections of transfer tubes. MOSkin dosimeters assembled over the DRP can
be used to alert of any dose discrepancies as a result of organ and/or applicator
motion. Both of the systems can verify that the correct plan is being delivered to the
patient, and can be easily incorporated into the existing clinical treatment flow.
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IVD can identify errors resulting from anatomical differences, such as inter- or intrafraction organ swelling or motion, however only if these directly affect the dose
delivered at the points of measurement. In the cases that the doses in those regions
are affected, the introduction of post-treatment imaging would provide a more
comprehensive quality assurance of the delivered treatment, allowing posttreatment reconstruction of the delivered dose distribution. The three components
of comprehensive HDR BT treatment QA are shown in figure 10.1.

Figure 10.1 Three components of comprehensive HDR BT QA.
Future applications of the DRP procedure for IVD are recommended to employ the
recently developed wireless MOSkin reader system, allowing readout without the
necessity of the long cables. Moreover, delivered and planned rectal wall dose
discrepancies should be evaluated in real-time, as opposed to the post-treatment
evaluation performed in this study. A newly assembled MVC system that employs a
higher number of diodes with optimized diode positioning is recommended to test
system ability to detect specific treatment errors. Studies of real-time dose and HDR
source monitoring should be implemented and evaluated in future studies to
determine its efficacy in alerting of dose discrepancies above the accepted error
margin.
It is important that the frequency and types of treatment errors are shared and
discussed among radiotherapy staff, so that these results can lead to an evolution of
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quality management systems in the clinic, and contribute to the reduction of
uncertainties and potential systematic errors. This in turn will improve cancer care
for the patient, and provide another stepping-stone in our battle with cancer.

10.3 Final conclusions
In this thesis, solid-state semiconductor dosimetry has united the fields of
geoscience and medical physics. Radiation measurement techniques have been
developed both for sediment dating, by applying the Timepix pixelated detector, and
for radiotherapy treatment verification, by applying MOSkin and diode detectors.
Using these methods, spatially resolved sediment dose rates have the potential to
improve the accuracy and precision of dating and allow a better understanding of H.
sapiens’ past, while real time radiotherapy treatment verification has the potential
to improve the quality and longevity of life for present-day and future H. sapiens.
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